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Abstract 
Transcription factors play a vital role in the biology of every organism. By controlling gene 
expression they regulate growth, development, metabolism, reproduction, signaling, and 
response to the environment. They have also provided the basis for many useful tools in 
molecular biology. The estrogen receptor alpha is one of the most studied human transcription 
factors and acts as a ligand controlled regulator of transcription. The modular design of this and 
other transcription factors allows for the rational design of artificial gene switches to control 
expression of desired genes. 
 
In this thesis I explore some tools for, and applications of, engineering the estrogen receptor. 
Beginning with two ligand binding domain mutants previously engineered to recognize the small 
molecules 4,4’-dihydroxybenzil (DHB) or 2,4-di(4-hydroxyphenyl)-5-ethylthiazole (L9), I 
showed that they could be used as a gene switch to independently control reporter genes in yeast 
and mammalian cells. By using different DNA binding domains, activation and repression 
domains, promoter elements, and a luciferase reporter I implemented the logic functions AND, 
OR, NAND, and NOR in HeLa cell culture. My research revealed some of the limitations of both 
the modular engineering approach, and the yeast two-hybrid screening assay used to engineer the 
ligand binding domain. I explored the feasibility of performing directed evolution of gene 
switches in mammalian cells through a protoplast fusion method, which combines the benefits of 
simple library creation with screening in a functionally relevant system. Although individual 
steps of the process were successful, the method proved unsuitable for large scale screening of 
libraries. The endogenous gene vascular endothelial growth factor-A (VEGF-A) was targeted for 
control by a gene switch.  The effect of construct design was evaluated using a VEGF-A 
promoter controlled luciferase gene and performance was impacted by the choice of DNA 
binding domain, activation domain, and the order of domain use. Endogenous VEGF-A protein 
secretion in HeLa cells was successfully upregulated twofold by a DHB ligand controlled gene 
switch.  Finally, I developed a useful biosensor for estrogenic compound detection that has the 
advantage of requiring no added substrates for signal generation. Through fusing the N and C 
terminal halves of the fluorescent protein Venus to the receptor ligand binding domain, 
fluorescence complementation generated a robust signal upon addition of an estrogenic ligand. 
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The biosensor was capable of responding to a range of endogenous, pharmaceutical, 
environmental, and industrial compounds with sensitivities that correlated with their relative 
binding affinity. The signal characteristics were seen to depend on the length of the LBD region 
used, with some constructs distinguishing between agonists and antagonistic ligands. 
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Chapter 1: Introduction 
1.1 Transcription Factors 
Transcription factors are proteins that control the timing and abundance of gene expression and 
thus lie at the heart of metabolism, development, and differentiation (1, 2). Their mutation or 
misregulation can lead to abnormal states such as cancer, inflammatory diseases, metabolic 
disorders, and congenital birth defects (3, 4, 5, 6). They are typically characterized by the 
presence of a DNA binding domain (DBD), activation or repression domains capable of 
influencing transcription, and protein interaction or regulatory domains. There are estimated to 
be around 1900 transcription factors in humans, most of which remain poorly characterized, that 
act in conjunction with the general transcriptional machinery to determine which genes are 
expressed at any given time (7). Their regulation and differential expression allow cells to 
respond to their environment and generate multiple cell phenotypes from a single genome. For 
these reasons, studies of transcription factors, and the gene regulatory networks they form, are of 
great interest. 
 
Research on transcription factors has resulted in a number of useful biological tools. Model 
transcription factors and promoter elements are widely used as inducible gene expression 
systems, for example protein production in E. coli controlled by LacI (8) or AraC (9), or gene 
expression in mammalian cells controlled via TetR (10, 11). The yeast two hybrid system was 
developed with the yeast GAL4 protein by recognizing that transcription factors consist of 
separable domains controlling DNA binding and transcriptional activation, and provides a useful 
assay to detect protein-protein interaction. The fusion of the GAL4 DBD to one protein and the 
GAL4 activation domain (AD) to another leads to induction of a reporter gene if the two proteins 
interact (12, 13). Many transcription factors are regulated by the binding of a small molecule, 
such as a metabolite or signaling compound, and thus can be converted into biosensors for 
compound detection or library screening purposes (14, 15). Site-specific genome modifications 
are challenging to perform in higher eukaryotes, but combining a DNA binding domain with the 
FokI nuclease domain has provided a solution. By cleaving the chromosome at a desired location 
using a zinc finger nuclease, homologous recombination with a DNA construct containing the 
desired alteration is greatly stimulated (16, 17, 18, 19, 20, 21). 
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Controlling gene expression through the use of transcription factors has many applications. 
Metabolic engineering involves the alteration of metabolism through the introduction of novel 
enzymes/pathways or the alteration of expression of existing genes within an organism, for the 
purpose of producing commercial or nutritional compounds of interest. Depending on the 
approach taken, transcription factors can be used to modulate expression of either individual 
genes or whole pathways in plants (22, 23, 24), E. coli (25, 26), or yeast (27, 28).  The recent and 
rapidly growing field of induced pluripotent stem cells (iPSC) was spurred by the discovery that 
the introduction of only four transcription factors (Oct3/4, Sox2, c-Myc, and Klf4) has the ability 
to reset the gene regulatory network and convert fibroblast cells into stem cells (29), and expands 
on observations that cellular identity can be modified by introducing alternate regulatory proteins 
(30). The iPSC field holds much promise for basic science, drug discovery, and therapeutic 
applications. Gene therapy, while slow to produce many clinical treatments, is being actively 
pursued and often involves the introduction of transcription factors. The first approved gene 
therapy treatment was in China and uses the p53 tumor suppressor transcription factor in the 
treatment of head and neck squamous cell cancer (31).  
 
1.2 Estrogen Receptor Alpha 
The estrogen receptor alpha (ERα) is a member of the steroid binding nuclear receptor family of 
transcriptional regulators and is one of the most highly studied transcription factors (7, 32, 33, 
34). It plays an important role in development and reproduction, and is implicated in a number of 
cancers. ERα was first cloned in 1985 (35, 36) and was subsequently discovered to act in 
conjunction with a related gene that was named estrogen receptor β to mediate estrogen signaling 
(37). The receptors are expressed in most tissues of the body, with ERα expressed mainly in 
reproductive tissues (uterus, ovary, testes), bone, breast, liver, kidney, fat, and the brain.(38). 
While gene deletion of the estrogen receptor in mice is not lethal, females were infertile and 
males had decreased fertility (39). 
 
Nuclear receptors have a common structure consisting of an N-terminal region, a conserved Cys4 
zinc finger DNA binding domain, a hinge region, a ligand-binding domain (LBD), and a C 
terminal region (Figure 1.1). Due to the highly dynamic nature of the receptors, the only full 
length structure is for the PPARγ-RXRα heterodimer (40). However, structures for various 
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domains have been published from a number of nuclear receptors (33). The N terminal A/B 
region contains a ligand independent activation function and regions involved in domain and 
coactivator interactions. The DNA binding C domain is highly conserved across all nuclear 
receptors. Crystal structures determined of the binding region complexed with DNA response 
elements showed that the structure was a distinctive two zinc finger domain, and revealed that 
the ER DBD made contact with four basepairs and organized a network of water molecules to 
stabilize the interaction with the estrogen response element (ERE) (41). The crystallized DBDs 
bound the DNA as a dimer, with direct contacts at the dimer interface. The symmetry that was 
seen explains the palindromic nature of the ERE half sites: AGGTCA NNN TGACCT. The D 
domain acts as a hinge region between the DNA binding domain and the ligand binding domain 
(E). The LBD is composed of 12 alpha helices that surround a central pocket for a hydrophobic 
ligand (42). The estrogen receptor is interesting in that it is capable of binding many different 
ligands that are produced endogenously, encountered in the environment, or produced as 
pharmaceuticals (43, 44). Upon binding of an agonist, helix 12 undergoes a conformational 
change that reveals a cleft in the protein capable of binding an LXXLL motif in coactivators 
(45), whereas antagonists act to position helix 12 such that coactivators can not bind (46). The 
LBD is also required for nuclear localization and dimerization, with the binding of ligand 
stabilizing dimers (47). The F domain has a modulatory function on dimerization, agonists, and 
antagonists (48). 
 
 
Figure 1.1. Estrogen receptor α domains. The amino acid positions and functional domains are indicated. 
 
ERα regulates the expression of genes in response to estrogenic compounds, typified by 17β-
estradiol, which bind to the ligand binding domain and cause a conformational change that 
recruits coactivators or corepressors. It can exert its effects in a genomic manner, by binding as a 
dimer to estrogen response elements or interacting with other transcription factors like AP-1, or 
in a non-genomic manner by affecting for example MAPK signaling pathways (49). Genome-
wide studies have examined estrogen receptor binding sites and it was found they are usually 
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more than 1 kb away from a gene’s transcriptional start site, and bind ERα to form long range 
loops of interacting chromatin regions coordinating gene expression (50, 51). 
1.3 Engineering Transcription Factors 
Much attention has been focused on protein engineering of transcription factors. One area has 
been the DNA binding domain since altering this region allows for control over the genes 
regulated. Evolution has produced multiple ways of binding DNA including the structure groups 
helix-turn-helix (eg LacI, homeodomain proteins), zinc coordinating (Cys2His2 zinc finger, 
nuclear hormone Cys4 zinc finger, p53 loop-sheet-helix, GAL4), zippers (leucine zipper, helix-
loop-helix), and others (52). Most classes of DBDs do not show an easily decipherable code 
between the amino acids in the protein and the sequence of DNA bound, the main exception 
being the Cys2His2 zinc finger (53, 54). This structure consists of a 30 amino acid module that 
coordinates a zinc ion between two cysteines and two histidines, with specific residues in a 
finger associating with a specific base, and multiple fingers arranged in a linear manner. The 
result is that one finger binds a triplet of DNA (with a fourth base overlapping the next finger’s 
triplet), with multiple fingers binding longer linear sequences. This modular arrangement was 
seized upon by researchers to engineer sequence specific DNA binding proteins (55, 56, 57), just 
as evolution had seized upon it and turned it into the most common DBD in humans with over 
700 examples (7). A recent DBD that also shows potential for engineering due to its simple 
recognition code is the TAL effector domain (58, 59). 
 
Regulation of transcription factors has also been a target of engineering. Nuclear hormone ligand 
binding domains have been engineered to respond to new ligands to control gene expression in 
an orthogonal manner (60, 61, 62, 63), and have also been used as ligand activated switches to 
control enzymes (64). Temperature controlled self splicing inteins have been developed to 
control transcription factor function (65). The use of different natural or engineered activation 
domains has been investigated to increase the activity of a transcription factor (66, 67). Likewise, 
repressors have been investigated and developed into useful systems (68). 
 
The approaches taken to engineer transcription factors have varied. Much research is based on 
rational design and the modularity of protein domains (69). An artificial transcription factor can 
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be constructed by fusing a DNA binding domain (either natural or engineered) with a known 
activation or repression domain, and optional regulatory domains. However there are often 
unexpected results from putting together separate components. Directed evolution can be a very 
useful tool for engineering both components and whole transcription factors, and can work in the 
absence of structural information (70). 
 
1.4 Gene Switches and Endogenous Gene Regulation 
The ability to regulate endogenous genes has applications in basic research as well as therapeutic 
relevance. A fundamental method of investigating gene function is to either knockout a gene, 
which involves a lot of time and expense, or to over-express an introduced copy which may not 
reproduce the natural splicing and regulation of the endogenous locus. By introducing factors 
that affect the natural locus a more flexible level of control can often be achieved. From a 
therapeutic perspective, introducing a transcription factor that affects the endogenous gene can 
produce a more natural mix of target gene splice variants (71).  
 
Many endogenous loci have thus far been targeted for regulation (72). The first human loci 
successfully targeted by an artificial transcription factor was the Erb-2 gene, commonly 
upregulated in cancer, which Barbas’s group used a six-finger engineered DBD to both up- and 
down-regulate (73). Another cancer related gene, MDR1 involved in multidrug resistance, was 
repressed using a five-finger DBD with the KRAB repressor (74). By targeting the erythropoietin 
gene, a hormone that controls red blood cell production and is therefore a therapeutic target for 
anemia, the importance of the chromatin structure was established with linker regions between 
nucleosomes allowing binding of the zinc finger (75). The vascular endothelial growth factor A, 
an essential regulator of blood vessel development and implicated in tumor growth, has been 
targeted by multiple groups by constitutively acting constructs (76, 77, 78, 79, 80) or by ligand 
activated constructs (81, 82). Other cancer related genes targeted include IGF2 and H19, bax, 
checkpoint kinase 2, and mammary serine protease inhibitor (83, 84, 85, 86). The cellular 
differentiation genes PPARγ and Oct4 have been successfully targeted (87, 88). 
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1.5 Estrogenic Compound Biosensors 
Biosensors are detection systems composed of biological material that can be used to monitor for 
particular ligands or metabolites (89). They can act in a variety of ways such as inducing a 
reporter gene with a convenient assay, by allowing an increase in cell growth, or they may be a 
protein that generates its own signal upon ligand interaction. Ligand controlled transcription 
factors, like ERα, can be converted into biosensors for the activating ligand. This can be 
beneficial for investigating which ligands will activate a response, for engineering specificity to a 
new ligand, or for metabolic engineering. The ligand binding domain is the key to this activity, 
and it can be removed from its native context to engineer systems that function in different ways. 
 
Multiple biosensors for nuclear hormone-like compounds have been developed that differ in the 
reporter used, and also in the host species (90). Assays have been developed for estradiol activity 
that are close to its natural activity, such as an increase in prepubertal mouse uterine weight or 
the growth of the estradiol responsive MCF-7 tumor cell line (91). While these have the benefit 
of being highly relevant physiologically, they take longer than other assays and are not useful 
from an engineering perspective. As ERα is a transcription factor, biosensors have been 
constructed simply by cloning a reporter gene such as β-galactosidase, luciferase, or EGFP under 
the control of estrogen receptor response elements and expressing these in yeast (92, 93, 94). 
Other studies have replaced the natural DBD with that of the yeast GAL4 transcription factor 
(95). Yeast one- or two-hybrid assays have been developed that rely on either a β-galactosidase 
reporter or a growth-based assay (96, 97, 98). Fluorescently tagged estrogen receptors or LBDs 
have been used to monitor ligand binding based on construct stabilization or Forster resonance 
energy transfer (99, 100, 101). Other systems have been developed based on complementation of 
split luciferase fragments expressed in mammalian cells (102), or ligand stimulated splicing out 
of inteins from a thymidylate synthase gene in bacteria (103).  
 
1.6 Project Overview 
The theme of this thesis was an investigation of tools and applications of transcription factor 
engineering, using the human estrogen receptor α as its basis. The work highlights the utility of 
the ERα structure from an engineering perspective and also reveals important limitations both of 
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the modular protein design approach, and of engineering gene switches using a system different 
from the intended application (yeast vs mammalian cells). 
 
Chapter 2 describes the use of previously engineered ERα ligand binding domains to control 
gene expression in yeast and mammalian cells. The GAL4 DNA binding domain was used in 
conjunction with LBDs engineered to respond to the small molecules DHB and L9 in order to 
demonstrate ligand dependent transcriptional activation of fluorescent protein reporter genes in 
yeast. These gene switch constructs were also functional in mammalian cells but the addition of 
activation or repression domains led to ligand independent activity, highlighting the 
unpredictability of modular engineering. A less sensitive DHB responsive LBD mutant, 4S, was 
seen to perform well with the addition of activation domains. Constructs were designed to create 
logic gates within mammalian cells. These results showed that ligand binding domains 
engineered from a single scaffold could be used to independently control genes, and that 
conceivably any number of orthogonal gene switches could be created using one engineering 
approach. 
 
Chapter 3 describes attempts to create a mammalian screening system for engineering gene 
switches. A protoplast fusion approach was taken which allows for library creation within E. coli 
and subsequent clonal transfer into mammalian cells in culture for screening. Despite multiple 
construct designs, a VEGF-A promoter induced green fluorescent protein reporter did not show 
significant induction by a gene switch. However, a reporter constructed under the control of a 
GAL4 responsive promoter was shown to be induced by constitutive or ligand dependent GAL4 
DBD containing gene switches. After integrating this reporter into the genome of HeLa cells, a 
library of ligand binding domain mutants was screened by protoplast fusion, but known 
functional mutants were not recovered, indicating that the approach was not suitable for gene 
switch engineering. A fluorescence complementation ligand sensor developed in Chapter 5 was 
used to investigate protoplast fusion as a means of engineering solely the ligand binding domain, 
but this also failed to isolate known functional mutants. The previously established yeast two-
hybrid screening system was used to isolate mutants that showed increased sensitivity to 
hexylresorcinol, but when these mutants were transferred into HeLa cells they exhibited a loss of 
sensitivity, again confirming the need for a well performing mammalian screening system. 
8 
 
Chapter 4 describes the creation of ligand controlled gene switches that activate the endogenous 
gene vascular endothelial growth factor A. The gene switch performance was seen to depend on 
its design, with the particular DNA binding domain, activation domain, and order of domains 
having an effect on both basal and induced expression levels, thus showing that even a rationally 
designed gene switch construct requires optimization that is not easily predictable. Using a 
VEGF-A promoter controlled luciferase reporter, up to 17 fold ligand-dependent induction was 
observed. The gene switch successfully stimulated a twofold induction of VEGF-A mRNA and 
secreted protein when introduced into HeLa cells in culture. 
 
Chapter 5 describes the creation of an estrogenic compound biosensor. A series of constructs 
were made consisting of fragments of a split mVenus fluorescent protein fused at several 
different N terminal and C terminal positions flanking the ligand binding domain of the estrogen 
receptor. When expressed in HeLa cells, construct 6 (ERα 312-595) showed a nine fold increase 
in fluorescence in the presence of estrogen receptor agonists or antagonists. Construct 2 (ERα 
281-549) discriminated between agonists and antagonists by showing a slight decrease in 
fluorescence in the presence of agonists while being induced by antagonists. The fluorescent 
signal increased over a period of 24 hours. Ligand titration curves performed with construct 6 
showed a good correlation with the known relative binding affinities of the compound. The 
sensor could detect a number of compounds of interest due to their potential as environmental 
endocrine disruptors. The lack of a substrate requirement, the speed of signal development, the 
potential for high throughput assays, and the ability to distinguish agonists from antagonists 
make this an attractive sensor. 
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Chapter 2: Engineering Orthogonal Ligand Specificity in a Single Scaffold 
2.1 Introduction 
Gene regulation systems that provide temporal and spatial regulation of target gene expression in 
response to small molecule ligands (small molecule-dependent gene switches or circuits) are 
powerful tools for gene therapy, tissue engineering, metabolic engineering, and functional 
genomics (1, 2). Notably, small molecule-dependent gene switches were recently used to 
generate induced pluripotent stem cells (iPS) for regenerative medicine (3, 4). The need for 
orthogonal regulatory elements is seen from a surge in interest in creating gene circuits, inspired 
by their electrical counterparts (5). 
 
Many different systems have been developed to regulate gene expression in mammalian cells (6). 
Some of these arose from prokaryotic gene regulation systems, while others are based on 
eukaryotic transcription factors. Most rely on the modularity of biological control systems 
through the linkage of specific DNA binding domains (DBD), activation domains (AD) such as 
VP16 from the herpes simplex virus (7) or p65 from the human NF-κB transcription factor (8), 
or repression domains such as the Kruppel-associated box (KRAB) from human zinc finger 
transcription factors (9), and may or may not be modulated by a ligand responsive domain (10). 
 
An early and successful approach was the development of elements from the tetracycline 
resistance operon of E. coli (11). The initial system fused the activation domain of VP16 to the 
TetR protein producing the tTA construct which localizes an activating function to promoters 
containing the tetracycline operator sequence (tetO), to which tetR binds in the absence of the 
antibiotic tetracycline (12). This formed a tetracycline repressible system (TetOFF), since it 
resulted in gene expression in the absence of tetracycline that was turned off by its addition. 
Improvements were subsequently made including the use of the more effective tetracycline 
derivative doxycycline (13), mutation of the TetR domain resulting in the variant rtTA and the 
TetON system that functions by requiring doxycycline for DNA binding and gene expression 
(13), mutation to reduce basal activity of rtTA (14), engineering of the activation domain VP16 
(15) or the use of the p65 activation domain (16), the addition of the KRAB repressor domain 
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(17), the addition of an androgen receptor ligand binding domain (18), and construction of 
autoregulatory systems (19). 
 
Control systems have also been derived from other bacterial operons. These include response to 
the streptogramin group of antibiotics through the use of the repressor pristinamycin-induced 
protein and its DNA binding site from E. coli (20). Macrolide antibiotics, such as erythromycin, 
were used to control expression through an erythromycin dependent transactivator and its DNA 
operator sequence from E. coli (21). The Pseudomonas putida repressor CymR and operator 
CuO elements from the p-cymene degradation pathway were combined to give a cumate 
controlled system (22). Phage, bacterial, and mammalian components were combined to produce 
the coumermycin/novobiocin regulation system where the p65 activation domain is fused to the 
N-terminal domain of the E. coli gyrase B protein, which is in turn linked to the phage lambda 
repressor DNA binding domain. The presence of the antibiotic coumermycin from Streptomyces 
stimulates the dimerization of the gyrase B subunits and therefore also the DNA binding 
domains, which can then bind the lambda operator sequence in the controlled gene. Novobiocin 
prevents dimerization, turning the switch off (23). The quorum sensing system from 
Streptomyces coelicolor has also been converted to an expression control system regulated by the 
butyrolactone SCB1 (24). 
 
Functional elements can be brought together by chemically induced dimerization. FKBP12 is 
protein that binds the immunosuppressant natural products FK506 and rapamycin (25). By using 
a dimeric form of FK506 called FK1012, two FKBP12 domains can be recruited and when fused 
to an activation domain and DNA binding domain this forms a ligand controlled gene expression 
system (26). Alternatively, the rapamycin-FKBP12 complex binds to FRAP (FKBP-rapamycin 
associated protein) (27), and by linking FKBP to a DNA binding domain and a FRAP fragment 
to p65, a rapamycin controlled switch was created (28). Alternative ligands for this system have 
been investigated to avoid the cell proliferation inhibitory effect of rapamycin (29). 
 
Other groups have taken inspiration from nuclear hormone receptors (NHRs) such as the 
progesterone, ecdysone, and estrogen receptors which offer desirable characteristics as gene 
switches for transcriptional control. These receptors are typically sequestered in the cytosol of 
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eukaryotic cells, becoming active only upon binding a small ligand, resulting in dimerization, 
translocation, and activation of promoters harboring specific responsive elements (30). With 
distinct domains for ligand binding, DNA binding and activation/repression functions, NHRs 
offer protein engineers the flexibility of creating chimerical transcriptional activators or 
repressors by modular design (31, 32). Access to organic synthesis of small molecule hormone-
like compounds (33) makes these natural allosteric transcriptional switches attractive targets for 
engineering. Nuclear hormone receptors enable a wide range of target protein expression levels, 
tunable in a ligand dose-dependent manner. NHR ligand binding domains have also been 
combined with other proteins to enable posttranslational control of protein function (34). 
Specificity re-engineering approaches involving NHRs have typically involved mutating the 
ligand-binding domain (LBD) to a form that is not activated by the natural ligand, but is instead 
activated by a synthetic small molecule hormone-like compound inactive against the wild type 
receptor LBD. When using components from eukaryotes, it is important to prevent crosstalk 
between the natural and designed systems to prevent unintended activation by endogenous 
signaling pathways. 
 
The antiprogestin system (35) is based on a progesterone receptor deletion mutant that binds to 
the progesterone antagonist mifepristone (RU486), but not to progesterone. The truncated ligand 
binding domain was fused to the GAL4 DNA binding domain and the VP16 activation domain 
creating a gene switch responsive to mifepristone (36). A longer region of the ligand binding 
domain, missing only the C-terminal 19 amino acids, was found to perform better (37), and the 
use of the p65 activation domain also improved performance (38). 
 
The ecdysone system is based on the insect steroid receptor involved in Drosophila 
morphogenesis. The ecdysone receptor was initially shown to respond to certain ecdysteroids 
when expressed in mammalian cells (39), but was subsequently discovered to act as a 
heterodimer with the Drosophila ultraspiracle protein (40), and as a gene switch acted best when 
heterodimerized with the retinoid X receptor and replacing the N-terminal region of EcR with the 
VP16 activator (41). Further development of the system involved testing different insect ligand 
binding domains and their mutagenesis to respond to particular ligands, the optimization of 
activation domains, and the construction of homodimerizing variants (42, 43, 44, 45, 46). 
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The estrogen receptor has also been used as the basis for gene control. Initial constructs showed 
the feasibility of adding the VP16 activation domain and the use of the GAL4 DNA binding 
domain for use in mammalian and yeast systems (32, 47, 48, 49, 50). The use of the KRAB 
repression domain and other DNA binding domains has been explored (51, 52, 53, 54, 55, 56). 
Alteration of the ER-α LBD allows the use of ligands other than 17β estradiol (E2), including 4-
hydroxytamoxifen and other synthetic compounds (57, 58). Previous research in the Zhao lab by 
Dr. Karuppiah Chockalingam and Ka-Chun Lai produced variants sensitive to the compounds 
4,4’-dihydroxybenzil (DHB) or 2,4-di(4-hydroxyphenyl)-5-ethylthiazole (L9) (Figure 2.1) by 
using sequential site-saturation mutagenesis and error prone PCR of the ligand binding pocket of 
the hERα-LBD (59, 60).  
 
Figure 2.1. Chemical structures of E2, DHB, and L9. 
The ability to control gene expression through cis regulatory sequences in DNA and trans acting 
protein or RNA molecules has allowed the construction of many artificial gene circuits and 
synthetic biology devices. These have been pursued for reasons including the generation of 
fundamental knowledge regarding natural gene transcription and developmental networks (61), 
and the creation of systems that can be of use in industry or medicine (62). Beginning with 
pioneering work in E. coli (63, 64), synthetic regulatory systems such as logic gates, 
transcriptional cascades, toggle switches, and oscillators were subsequently developed in 
mammalian systems (65). 
 
The goal of this chapter was to demonstrate that the engineered ligand/LBD pairs DHB/7S and 
L9/L7E (Figure 2.2) can be used to independently control genes in yeast and mammalian cells, 
and the results have been published (66). The orthogonal pairs were used to control expression of 
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fluorescent proteins in yeast. A synthetic biology approach was taken to show the functionality 
of these pairs in mammalian cells through the construction of gene circuit logic gates. Finally, it 
was shown that the engineered LBDs did not act predictably when fused to other functional 
domains. Portions of this chapter are reproduced with permission from: McLachlan MJ, 
Chockalingam K, Lai KC, and Zhao H. (2009) “Directed evolution of orthogonal ligand 
specificity in a single scaffold”. Angewandte Chemie International Edition 48:7783-7786. 
Copyright Wiley-VCH Verlag GmbH & Co. KGaA. 
 
 
Figure 2.2. The locations of mutated sites are shown for mutant 7S (a) and L7E (b). The DHB and L9 
ligands were docked into the cavity left by E2 in the crystal structure of hERα-LBD-E2 (PDB code 
1GWR), as described elsewhere (59). 
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2.2 Results and Discussion 
2.2.1 Orthogonality of Engineered Ligand Binding Domains 
In order to determine the orthogonality of the DHB and L9 responsive ligand binding domains, 
the yeast two-hybrid system used for screening was employed to determine the sensitivity to E2, 
DHB, and L9 for the best mutant generated at each of the seven rounds of protein engineering 
(59, 60). The system functions by ligand induced activation of a gene switch construct consisting 
of the GAL4 DNA binding domain (amino acids 1-147) fused to ERα ligand binding domain 
variants (amino acids 312-595). This interacts with the steroid receptor coactivator 1 (SRC1) / 
GAL4 activation domain construct to transcribe a GAL-responsive histidine biosynthesis 
reporter gene, allowing growth of the yeast in media lacking histidine. Remarkable sensitivity 
and specificity were apparent with 7S/DHB and L7E/L9 pairs. While not quite as sensitive as the 
native estrogen receptor is for its ligand E2, both 7S and L7E showed nanomolar sensitivity to 
their respective ligands (Figure 2.3 and Table 2.1). The mutant 7S was 850-fold more sensitive 
toward DHB than the WT, around 300,000-fold less sensitive to E2, representing over 2.5x109 
fold specificity shift, and only showed a response to L9 at micromolar concentrations. The 
mutant L7E was 3,400-fold more sensitive to L9 than the WT, and showed no response to E2 or 
DHB at concentrations up to 10-5 M. Throughout the process of engineering, the DHB and L9 
series of mutants were fully orthogonal to each other, exhibiting no crossreactivity at micromolar 
or lower ligand concentrations. (Book 4 pg8-28) 
 
Table 2.1. The best mutant for each round of mutagenesis, the mutations it contained, and the point of 
half-maximal induction (EC50) for the ligands E2, DHB, and L9 from the yeast two-hybrid growth assay. 
The data is shown as the mean and standard error of the mean expressed in nM (nd = not detected) (66). 
Clone E2 EC50 DHB EC50 L9 EC50 
WT 0.15 (0.044) 560 (170) 4800 (380) 
1S (A350M) 0.71 (0.26) 10 (4.1) 46000 (18000) 
2S (A350M, L346I) 33 (0.57) 3.5 (0.068) 39000 (5700) 
3S (A350M, L346I, M388Q) 936 (280) 39 (2.8) nd 
4S (A350M, L346I, M388Q, G521S, Y526D) nd 44 (4.4) nd 
5E (A350M, L346I, M388Q, G521S, Y526D, F461L, V560M) nd 69 (19) nd 
5S (A350M, L346I, M388Q, G521S, Y526D, G442Y) 200000 (39000) 8.3 (1.6) nd 
6S (A350M, L346I, M388Q, G521S, Y526D, G442Y, L466S) 35000 (14000) 2.5 (0.30) 130000 (35000) 
7S (A350M, L346I, M388Q, G521S, Y526D, G442Y, Y459N, L466S) 44000 (26000) 0.66 (0.16) 20000 (5200) 
L1S (G521T) 350 (11) 30000 (3400) 370 (16) 
L2S (G521T, H524Y) nd nd 300 (17) 
L3S (G521T, H524Y, M388F) nd nd 46 (4.8) 
L4S (G521T, H524Y, M388F, T347C) nd nd 36 (2.0) 
L5S (G521T, H524Y, M388F, T347C, M528E) nd nd 3.7 (0.18) 
L6S (G521T, H524Y, M388F, T347C, M528E, I424V) nd nd 4.1 (0.18) 
L7E (G521T, H524Y, M388F, T347C, M528E, I424V, V376A) nd nd 1.4 (0.40) 
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Figure 2.3. Sensitivity of gene switch mutants to hormone in a yeast two-hybrid growth assay. (a) 
Growth of mutants in estradiol. (b) Growth of DHB mutants with DHB ligand. (c) Growth of L9 mutants 
with L9 ligand. (d) Growth of L9 mutants with DHB, and DHB mutants with L9. 
  
The engineering of ligand binding domains has proven to be a fruitful research area. Amongst 
the family of NHRs, the LBD of the human estrogen receptor α (hERα) has proven to be a 
particularly versatile platform for the creation of orthogonal ligand-receptor pairs (57, 58, 59, 67, 
68, 69). This is perhaps not surprising given that the evolution of nuclear hormone receptors has 
followed a similar process, with mutations conferring sensitivity to new ligands deriving from an 
ancestral estrogen receptor gene (70). Early research showed that single residue changes could 
affect ligand binding of ERα, often discriminating between agonists and antagonists such as the 
G521R mutation which decreases E2 binding but retains binding of 4-hydroxytamoxifen (57, 71, 
72). More extensive mutagenesis approaches with the specific goal of creating orthogonal 
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ligand/ligand binding domain pairs have been attempted (67, 68, 69, 73, 74). Of these efforts, 
and efforts to shift the ligand specificity of other NHR LBDs (75), the 7S/DHB and L7E/L9 pairs 
represent two of the best examples of ligand specificity reversal reported (66). 
 
2.2.2 Control of Target Genes in Yeast 
By adding the 7S/DHB and L7E/L9 pairs to the ERα/E2 pair, three orthogonal estrogen receptor 
α based gene switches were available in yeast (Figure 2.4a). As these had so far only been used 
to control the GAL4 induced HIS3 reporter gene, it was necessary to demonstrate that other 
genes could be controlled. The green fluorescent protein GFP, yellow fluorescent protein YFP, 
and a red fluorescent protein mCherry were chosen as target genes for their ease of detection. 
They were cloned under the control of the yeast gal1 promoter which contains GAL4 response 
elements, hence enabling control by the GAL4-LBD gene switch. An alternative construct design 
was also investigated by cloning the fluorescent proteins under the GAL417mers(x3)-TATACYC1 
promoter that controls the β-galactosidase gene in the yeast two-hybrid strain YRG2. This 
promoter showed a high constitutive expression of the reporters in the absence of the gene switch 
and so was not investigated further. 
 
Three reporter strains were constructed. These contained the wildtype switch with GFP, the 7S 
switch with mCherry, and the L7E switch with YFP. In the absence of ligand the strains showed 
little expression of the reporter, although some expression of YFP was visible. When these 
strains were exposed to each ligand, activation was observed only in the presence of the correct 
ligand. E2 stimulated expression of GFP, DHB stimulated expression of mCherry, and L9 
stimulated expression of YFP (Figure 2.4b). (Book 4 pg 100) 
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Figure 2.4. (a) Dose-response curves for WT, 7S, and L7E in the presence of E2, DHB, or L9. (b) Gene 
switches controlling the expression of fluorescent proteins in yeast from a Gal1 promoter. Row one 
contains GFP + WT, row two contains mCherry + 7S, row three contains YFP + L7E. The three columns 
contain 10-7 M E2, DHB, or L9 from left to right.  
 
2.2.3 Construction of Mammalian Gene Switches  
The next goal was to examine the performance of the gene switches in mammalian cells. The 
GAL4-LBD constructs from yeast were cloned into the pCMV5 vector which allows strong 
constitutive expression in mammalian cells from the cytomegalovirus derived promoter. When 
expressed in HeLa cells with a GAL4 responsive luciferase reporter, 7S and L7E gave 11-fold 
and 33-fold induction, respectively, compared to a 67-fold induction from the wild type LBD 
(Figure 2.5a). The engineered switches showed no appreciable induction with either E2 or the 
non-specific ligand up to 1000 nM, while the wild type ligand binding domain construct showed 
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induction with both DHB and L9 ligands at 100 nM and above (Figure 2.5b). (Book2 pg281 – 
Book3 pg11) 
 
Figure 2.5. Induction of luciferase in HeLa cells by the GAL4-LBD format gene switches. (a) Gene 
switch activity in the presence of the target ligand. (b) Gene switch activity in the presence of non-target 
ligands. 
 
2.2.4 Mammalian Gene Switch Domain Addition 
The addition of other functional domains to the engineered LBDs would allow for targeting of 
different promoters, give more control over the activation, or allow for repression of genes. 
Attempts to use the 7th round L9 mutant ligand binding domain in different construct designs 
gave unanticipated results. To test its versatility, L7E was cloned into a construct containing the 
engineered zinc finger DNA binding domain N1 (whose binding target is GGG GTA GAA) and 
the activation domain VP64 (four copies of the VP16 core activation domain residues) (31). 
When expressed in HeLa cells with an N1 responsive luciferase reporter, a high basal activity 
and minimal induction was observed (Figure 2.6a). To examine if this effect was due to the N1 
DBD, GAL4 DBD-containing constructs were used with the activators VP16 or VP64 (Figure 
2.6b,c). In both cases the activation domain caused an increase in basal expression, resulting in 
only a few fold activation with the L9 ligand. Using different lengths of the C-terminal F domain 
of the ERα, a region that modulates the receptor function (76, 77), did not relieve the ligand 
independent expression (Figure 2.6b). Another activation domain, p65, was tested, but this too 
showed the same pattern whether it was present at the N or C terminus of the gene switch (Figure 
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2.6d). Thus changes in the DBD or activation domains resulted in a poor ability of L7E to confer 
ligand dependent activity. (Book 2 pg 171, 200, 231) 
 
 
 
Figure 2.6. Performance of the L7E ligand binding domain in mammalian constructs. (a) L7E was cloned 
into a construct containing the N1 engineered zinc finger DNA binding domain and the VP64 activation 
domain and transfected with an N1 responsive luciferase reporter. (b) The effect of the F domain on 
constructs containing the VP16 activation domain. (c) The effect of adding VP16 or VP64 activation 
domains to the functional GAL-L7E construct. (d) The effect of adding the p65 activation domain at the 
N or C terminus. Data is the mean and standard deviation of duplicate samples. 
 
During a set of unrelated experiments it was observed that the addition of a tag modified the 
performance of the gene switch. A codon optimized yellow fluorescent protein (EYFP), or the N 
terminal or C terminal half when split at position 155, was fused next to the p65 domain and 
reduced preferentially the basal level of reporter expression. This effect was seen both with the 
4S DHB LBD and the L7E L9 LBD. When fused at the C terminus of p65-GAL-4S, EYFP 
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reduced basal expression of a luciferase reporter by 40 % and the induced expression only 20 % 
(Figure 2.7a). The fusion of the half tags reduced basal expression even further while decreasing 
the induced level by three fold. By reducing basal expression more than the induced expression, 
the result was a higher ratio of induction, with the YN C-terminal tag almost doubling the ratio to 
over 100 fold induction. The phenomenon was more pronounced when the tags were added at the 
N-terminus, with 600 fold induction observed with YN-p65-GAL-4S (Figure 2.7b). (Book 5 pg 
251-283) 
 
Figure 2.7. EYFP tag has an effect on gene switch performance. The EYFP gene, YN (EYFP residues 1-
154), or YC (EYFP residues 155-239) were fused to the C-terminus (a) or N-terminus (b) of the p65-
GAL-4S gene switch. (c) Recovery of some inducibility of the p65-GAL-L7E construct by the fusion of 
YN at its N-terminus. Samples show the induction of a GalTATA-luciferase reporter in the absence and 
presence of 1 µM DHB or L9 ligand, normalized such that the p65-GAL-LBD construct in the absence of 
ligand equaled 1. Data is the mean and standard deviation of duplicate samples. 
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To see if this tag could improve the ligand-dependent induction of the L7E LBD, YN was fused 
at the N-terminus of p65-GAL-L7E and compared to the well performing GAL-L7E (Figure 
2.7c). A 10 fold induction ratio was observed, which was an improvement over the non-tagged 
construct even though it was lower than the ratio for the GAL-L7E and still showed a high basal 
activity. Fusion tags such as His6, maltose binding protein, hemagglutinin (HA), or fluorescent 
proteins are commonly used in biochemistry to allow for easy purification of proteins (78), or 
visualization of their activity in vivo. While tags are often specifically used to improve 
expression or solubility of a protein (79), their effect on protein function can sometimes be 
overlooked, leading to misattribution of an effect to the protein of interest rather that the tag 
itself (80, 81). These results are a useful reminder that all components of a fusion protein 
construct should be examined, even those that are not expected to have a functional effect. 
 
 
Figure 2.8. Luciferase induction in HeLa cells with the addition of p65 activation domain and GAL4 
activation domain at the N-terminus of the LBDs of hERα, 7S, and L7E. The expression in the absence 
and presence of 1 µM ligand was normalized such that the 0 M value for p65GALER was equal to 1. 
 
To determine whether the suboptimal performance was specific to the L7E engineered ligand 
binding domain, the 7th round DHB LBD 7S was also tested in different configurations. A 20-
fold increase in basal expression was observed when using the NFκB p65 activation domain with 
either the 7S or L7E LBD, in contrast to its use with the wild type LBD (Figure 2.8). Although 
the presence of ligand did lead to an induction of luciferase, it was only by 4-fold. The use of a 
different activation domain, the strong viral VP16, indicated that the increase in basal expression 
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was not due to p65 but was caused by the engineered ligand binding domain itself. Since the 4th 
round DHB mutant had been observed to function well with additional domains (Figure 2.7) a 
series of constructs were made comprising the GAL4 DNA binding domain, the 4S to 7S DHB 
mutants, and VP16. The fourth round mutant 4S gave strong induction when measured in a HeLa 
cell based luciferase assay, but the 5S, 6S, and 7S variants showed increasing basal expression at 
each round (Figure 2.9). A similar panel of L9 variants was examined, containing the fourth to 
seventh round LBDs, and it was found that all showed high basal activity (data not shown). 
(Book4 pg121-127, 163-167) 
 
Figure 2.9. Luciferase induction in HeLa cells for DHB mutants 4S, 5S, 6S, and 7S with a C-terminal 
VP16 activation domain. The values were normalized such that the 0 M value for GAL4SVP16 was equal 
to 1. 
 
To expand the use of the gene switch system, the ability to repress transcription was investigated 
through the use of the KRAB domain. A constitutively expressing reporter was constructed by 
inserting the strong cytomegalovirus immediate early promoter (CMV) upstream of the Gal 
response elements of GalTATA-Luciferase, giving a highly expressing construct that should be 
repressible through trans factors binding at the Gal elements. The KRAB domain was cloned at 
either the N or C terminus of GAL-LBD constructs and its activity on the reporter was monitored 
in HeLa cells (Figure 2.10). The KRAB domain was functional. However, repression was 
predominantly ligand independent with 85-95 % repression in the absence of ligand. Only 2-4 
fold further repression was observed upon addition of ligand. (Book 2 pg 279, Book 3 pg 18) 
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Since the use of the GAL DBD with the KRAB domain was not ligand dependent, the use of the 
full length ERα was investigated. Previous research by de Haan et al. had shown that tagging 
both the N and C termini of ERα yielded an effective estrogen response element targeting 
repressor, despite some ligand independent activity (82). After fusing the KRAB domain at each 
end of the full length 7S variant, 4-fold repression in the absence of ligand was observed, but this 
was relieved by the introduction of the G400V (50) mutation to the ligand binding domain 
(Figure 2.11). This K7SK-G400V construct had 40 % repression without DHB, but a further 10 
fold repression upon the addition of ligand. 
 
 
Figure 2.10. KRAB repression domain added to GAL-LBD gene switch constructs at the C terminus (a) 
or the N terminus (b). Constructs were expressed in HeLa cells with the constitutive but GAL responsive 
reporter CMVgalTATA-Luciferase in the presence or absence of 1 µM estradiol, L9, or DHB ligand. 
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Figure 2.11. Luciferase repression in HeLa cells from switches with the KRAB repression domain 
attached to the 7S LBD and human ERα DNA binding domain, in the absence and presence of 1 µM 
DHB. The values were normalized such that the 0 M value for the CMV-2ERE-Luciferase reporter was 
equal to 1. 
 
These results highlight the difficulty in engineering truly modular components for synthetic 
biology. While the 4S DHB responsive LBD showed flexibility in terms of the domains it could 
function with, the 7th round DHB and L9 LBDs were recalcitrant to context modifications. Due 
to unanticipated interactions between protein domains, one cannot simply cut and paste 
components, showing that the engineering approach should be as close as possible to the 
intended application. Failure rates of up to 76 % have been reported for the assembly of designed 
zinc finger modules (83), supporting the complexity of modular design shown here. A crystal 
structure of the full length estrogen receptor bound to both ligand and DNA would be useful in 
identifying inter domain contacts that could be implicated in the constitutive activity of the 
engineered LBDs once they are in the context of different domains. However, only isolated 
domains of the ERα including the LBD and DNA binding domain have been crystallized (84, 
85). Indeed, the only intact nuclear receptor complex crystal structure, the PPAR-γ-RXR-α 
heterodimer bound to DNA, does show interactions between the PPAR-γ ligand binding domain 
and both DNA binding domains (86). 
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2.2.5 Construction of Logic Gates 
To demonstrate the utility of the engineered ligand/receptor pairs for creation of genetic circuits 
in mammalian systems, the logic functions AND, OR, NAND, and NOR were implemented in 
HeLa cells using a luciferase reporter, Gal4 or estrogen receptor DNA binding domain promoter 
response elements (GalRE or ERE), wild type or engineered ligand binding domains, and the 
KRAB repressor domain.  These were transiently transfected into HeLa cells in the presence of 
ligand and the luciferase gene expression was monitored. 
 
The AND gate (Figure 2.12a) was constructed with a constitutively expressed GAL4-L7E 
switch, a GalRE controlled ER-7S switch, and an ERE controlled luciferase gene. Induction of 
luciferase was mainly observed when both L9 and DHB ligands were present (140-fold), 
although some leaky expression was observed when either ligand was present alone. The OR 
gate (Figure 2.12b) was constructed by using a luciferase reporter downstream of both GAL4 
and estrogen receptor response elements, with constitutively expressed GAL4-L7E and ER-7S 
switches. This resulted in luciferase induction in the presence of L9 (100-fold), DHB (40-fold), 
or both (600-fold). The NAND gate (Figure 2.12c) was made with the strong constitutive CMV 
promoter with an inserted ERE, a constitutively expressed GAL4-L7E switch, and a GAL 
responsive KRAB-ER-KRAB G400V switch. The most repression of luciferase was observed in 
the desired L9 + E2 condition. However, this was only 4-fold with 2-fold repression observed in 
the presence of E2 alone. This indicates that presence of some leaky expression or ligand-
independent repression. The NOR gate (Figure 2.12d) was comprised of constitutively expressed 
KRAB-ER-L7E-KRAB-G400V or KRAB-ER-7S-KRAB-G400V switches, with luciferase 
downstream of a constitutive cytomegalovirus (CMV) promoter with an inserted ERE. This 
showed 10-16 fold repression in the presence of L9, DHB, or both ligands. (Book4 pg 162) 
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Figure 2.12. Logic gates in HeLa cells. The graphs show luciferase activity (mean, standard error) 
normalized to β-galactosidase expression, and with the value for the ethanol treatment taken as equal to 1. 
(a) AND gate with 10-8 M L9, DHB, or both. (b) OR gate with 10-8 M L9, DHB, or both. (c) NAND gate 
with 10-6 M L9, E2, or both. (d) NOR gate with 10-6 M L9, DHB, or both. 
 
As seen from Figure 2.12, some of the logic gates were more successful than others. The NOR 
gate performed best, giving a consistent repression in each of the ligand conditions. This is likely 
due to both gene switches being of a similar format, and the presence of only one type of binding 
site in the reporter preventing any synergistic effects. While the OR gate showed high induction 
in the presence of any ligand, there was a large difference between the single ligands and the 
DHB + L9 condition. The synergistic effect observed could be due to both the GalRE and ERE 
being bound, increasing the recruitment of the transcriptional machinery. Synergistic action at 
promoters is a well established concept whereby binding to a promoter element is enhanced by 
dimerization, cooperative binding of transcription factors, or heterosynergy between bound 
transcription factors and the basal transcriptional machinery (87, 88, 89). Promoter engineering 
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could be attempted to create interference between the binding sites, such as interspersing the Gal 
and estrogen response elements, in order to reduce the synergy. Other synthetic logic gates in 
mammalian cells have also shown leaky expression and synergy. In the creation of BioLogic 
gates from the Fussenegger group (90), tetracycline, streptogramin, macrolide, and butyrolactone 
control systems were used to create multiple logic functions. Their NAND gate showed 
repression with single inputs, and their OR gate showed a two-fold difference in induction 
between single and double inputs. 
 
More extensive synthetic devices have been engineered in mammalian cells. An oscillating 
signal generator was constructed using destabilized fluorescent proteins controlled by 
tetracycline and pristinamycin elements (91). Linkage of a synthetic circuit to an endogenous 
metabolite was demonstrated by controlling the level of uric acid in urate oxidase deficient mice 
(92). Intercellular signaling was demonstrated through the use of acetaldehyde as a signaling 
molecule (93). These two examples are of interest because the controlling signal is generated in 
vivo. Future directions are likely to involve generating tighter control over expression, more 
interfaces with endogenous signals, better engineering of DNA binding domains to target any 
gene, and an output that affects cell morphology or development (94, 95). 
 
2.3 Conclusions and Outlook 
In summary, a single scaffold was used in an effective and repeatable manner for the generation 
of two orthogonal ligand-receptor pairs, which had virtually a complete reversal of ligand 
specificity. The three pairs (E2/ERα, DHB/7S, and L9/L7E) were shown to independently 
control target genes in yeast and despite a lack of receptor based logic gates (5, 65), they were 
successfully combined into higher order functions as exemplified by the creation of logic gates in 
mammalian cells. It is envisioned that any number of further pairs could be generated in the 
same way for the development of new small molecule regulated gene expression systems. 
 
However, important limitations of the modular engineering approach were revealed in these 
experiments. Although the GAL4-LBD construct that was used for engineering in yeast 
performed well in mammalian cells, the most sensitive DHB and L9 responsive ligand binding 
domains were not transferable to other construct designs without the presence of high basal 
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activity. These effects were neither predictable from the yeast screening system nor from the 
corresponding ERα construct, and suggests that the screening system used for engineering gene 
switches should be as close to the intended application as possible. 
 
The different ligand controlled gene expression systems developed have different advantages and 
disadvantages. The tetracycline-based system has enjoyed wide usage and is generally 
considered to have few adverse effects (96), but the non-human elements have been shown to 
generate an immune response, especially in primates, that reduces the system’s effectiveness (97, 
98). Another limitation with the tetracycline-based system is that tetracycline and its related 
compounds will accumulate in developing bone and teeth, so they are contraindicated during 
pregnancy and childhood (99). The VP16 activation domain used in this and other systems has 
been shown to inhibit gene expression when present at high levels (100, 101), likely because it 
sequesters factors involved in transcription. 
 
The nuclear hormone receptor systems have the benefit of using mainly human-derived 
components, which should reduce immunogenicity if the system is to be used for gene therapy. 
The exception is the ecdysone receptor since its origins lie in insect proteins, and this could also 
interact with the retinoid X receptor in mammalian systems. The progesterone system suffers 
from detrimental public perception due to its ligand, mifepristone/RU486, being an abortive 
agent even though it would be used at a much lower concentration than needed for this effect. 
Some of the systems are limited to a single ligand or group of related ligands, making it 
necessary to use different systems to control multiple genes simultaneously. The receptor 
systems that allow engineering of the ligand binding domain could use the same basic format but 
with different LBDs for this purpose. 
 
The benefits of the engineered estrogen receptor-based system include the use of only human-
derived protein domains, an engineering approach that allows tailoring of the system to respond 
to drugs having favorable kinetics and pharmacology, and the ability to use different ligands to 
control multiple targets independently. An ideal gene switch system would be immune-system 
friendly (which may be more likely with mammalian components), flexible in the promoters that 
it can target by using different DNA binding domains, and be expandable to new inducers.  
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A number of future directions are possible. The ligands used here are not ideal for gene switch 
systems since they are neither readily available nor approved for use in humans. Approved 
compounds with known pharmacology could be used as new targets for specificity engineering. 
New screening methods could be developed to avoid unexpected results from switching from a 
yeast based environment to a mammalian one. 
 
2.4 Materials and Methods 
2.4.1 Chemicals, Media, and Reagents 
DNA polymerase, restriction enzymes, and T4 DNA liagse were from New England Biolabs 
(Beverly, MA). Chemicals were from Sigma-Aldrich (Carlsbad, CA). Media components were 
from BD Biosciences (San Jose, CA), and premixed synthetic complete amino acid dropout 
mixes were from MP Biomedicals (Irvine, CA) or Sigma-Aldrich (Carlsbad, CA). Cell culture 
media were from the UIUC cell media facility (Urbana, IL). The ligands DHB and L9 were 
synthesized by Professor John Katzenellenbogen’s laboratory (Urbana, IL). DNA isolation and 
miniprep kits were from Qiagen (Valencia, CA), and yeast miniprep kits were from Zymo 
Research (Orange, CA). 
 
2.4.2 Yeast Two-Hybrid Ligand Titration 
Frozen stocks of the DHB and L9 series mutants were streaked on synthetic complete medium 
minus leucine / tryptophan (SC-LW) plates and grown for two days. A colony was picked and 
grown overnight to saturation in SC-LW media and then diluted to an OD of 0.002 in synthetic 
complete medium minus leucine / tryptophan / histidine (SC-LWH). 190 µL of the diluted yeast 
culture was placed into wells of a flat bottomed 96-well plate, to which was added 10 µL of 
ligand diluted 50-fold in SC-LWH media to give a final ligand dilution of 1000-fold. Ligand 
concentrations of E2, DHB, and L9 of 10-11 M to 10-5 M were tested, as well as the absence of 
any ligand. Plates were grown at 30 °C in a box containing wet paper towels to minimize 
evaporation. After 26-28 hours of growth, each well was resuspended and the optical density at 
600 nm was measured using a Spectramax 190 microplate reader (Molecular Devices, Sunnyvale 
CA). 
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2.4.3 Fluorescent Yeast 
Plasmids were transformed into yeast strain YM4271 (MATa, ura3-52, his3-200, ade2-101, lys2-
801, leu2-3, 112, trp1-901, tyr1-501, gal4-∆512, gal80-∆538, ade5::hisG) (Clontech, Mountain 
View, CA) by the lithium acetate method (102) in various combinations, and selected for on 
synthetic complete medium minus leucine / tryptophan / uracil (SC-LWU) plates. The GFP 
reporter was transformed in conjunction with the yeast two-hybrid plasmids pBD-Gal4-WT and 
pGAD424-SRC1. The mCherry reporter was transformed with pBD-Gal4-7S and pGAD424-
SRC1. The YFP was transformed with pBD-Gal4-L7E and pGAD424-SRC1. The strains were 
grown overnight in SC-LWU media at 30 °C and 200 µL was inoculated into 2 mL yeast extract 
peptone adenine dextrose (YPAD) media with 10-7 M ligand and grown overnight. The cells 
were pelleted, washed with phosphate buffered saline (PBS), resuspended in 50 µL PBS, and 
transferred to a 96-well plate. The plate was placed on a UV illuminator (Spectroline, Westbury 
NY) producing 435 nm light and photographed. 
 
2.4.4 Cell Culture and Transformation 
HeLa cells were grown in minimal essential medium (MEM) plus 1 mM sodium pyruvate, and 
10% fetal bovine serum (FBS) (UIUC Cell Media Facility, Urbana, IL) at 37 °C with 5% carbon 
dioxide. When cells were 80% confluent, they were trypsinized and split into 24-well plates with 
MEM media plus 1 mM sodium pyruvate, and 5% charcoal dextran stripped calf serum (UIUC 
Cell Media Facility). Cells were grown for 24 hours until they were over 90% confluent and 
transfected using 1.5 µL lipofectamine 2000 (Invitrogen, Carlsbad CA), 100 ng β-galactosidase 
expression plasmid, 690 ng luciferase reporter plasmid, and 10 ng of the relevant gene switch 
plasmids per well. After four hours, the media was changed to MEM media plus 1 mM sodium 
pyruvate, and 5% charcoal dextran stripped calf serum, plus E2, DHB, or L9 ligand. Cells were 
incubated for 24 hours, then lysed and assayed for luciferase activity using the Luciferase Assay 
System (Promega, Madison WI). Luciferase levels were normalized to β-galactosidase 
expression. 
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2.4.5 Cloning of Expression Constructs 
Standard molecular techniques were used to create the constructs used in these experiments. For 
the mammalian constructs the ERE controlled luciferase construct (2ERE-pS2-pGL3-Luc) has 
been used previously (59). Gal response elements or the constitutive expression element CMV 
were added by blunt ligation upstream of the ERE element. The p65 domain was cloned from a 
plasmid gifted from the Hillen laboratory. The N1 and KRAB domains were cloned from 
plasmids gifted from the Barbas laboratory. Constitutively expressed gene switches were cloned 
between the KpnI and BamHI sites of pCMV5. Inducible gene switches were cloned by 
replacing the luciferase gene under the relevant promoter. For the yeast fluorescent protein 
constructs, the gal1 promoter was amplified by PCR from genomic DNA and cloned upstream of 
GFP, mCherry, or YFP. The constructs discussed in this chapter are shown in Table 2.2. 
 
Table 2.2. Constructs used in this work. 
HZ Genotype Plasmid Details 
2391 YRG2 pGAD424-SRC MATa ura3-52 his3-200 ade2-101 lys2-801 
trp1-901 leu2-3 112 gal4-542 gal80-538 
LYS2::UASGAL1-TATA GAL1-HIS3 
URA3::UASGAL4 17mers(x3)-TATACYC1-
lacZ 
886 YRG2-SRC ER pBD Gal4-CAM  
887 YRG2-SRC 1S pBD Gal4-CAM  
888 YRG2-SRC 2S pBD Gal4-CAM  
889 YRG2-SRC 3S pBD Gal4-CAM  
890 YRG2-SRC 4S pBD Gal4-CAM  
891 YRG2-SRC 5E pBD Gal4-CAM  
892 YRG2-SRC 5S pBD Gal4-CAM  
893 YRG2-SRC 6S pBD Gal4-CAM  
894 YRG2-SRC 7S pBD Gal4-CAM  
895 YRG2-SRC L1S pBD Gal4-CAM  
896 YRG2-SRC L2S pBD Gal4-CAM  
897 YRG2-SRC L3S pBD Gal4-CAM  
898 YRG2-SRC L4S pBD Gal4-CAM  
899 YRG2-SRC L5S pBD Gal4-CAM  
900 YRG2-SRC L6S pBD Gal4-CAM  
901 YRG2-SRC L7E pBD Gal4-CAM  
1034 YM4271  MATa, ura3-52, his3-200, ade2-101, lys2-801, 
leu2-3, 112, trp1-901, tyr1-501, gal4-∆512, 
gal80-∆538, ade5::hisG 
1734 YM4271 gal1p-GFP-pRS426, pGAD424SRC, ER-pBD-Gal4-CAM  
1739 YM4271 gal1p-YFP-pRS426, pGAD424SRC, L7E-pBD-Gal4-CAM  
1740 YM4271 gal1p-mCherry-pRS426, pGAD424SRC, 7S-pBD-Gal4-CAM  
3124 DH5alpha N1-L7E-VP64 pcDNA3  
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Table 2.2 (cont). Constructs used in this work 
HZ Genotype Plasmid Details 
620 DH5alpha CMVgalTATA-Luciferase pGL3  
621 DH5alpha Gal-L7E pCMV5  
622 DH5alpha Gal-ER pCMV5  
623 DH5alpha Gal-7S pCMV5  
624 DH5alpha Gal-L7E-KRAB pCMV5  
625 DH5alpha Gal-ER-KRAB pCMV5  
626 DH5alpha Gal-7S-KRAB pCMV5  
631 DH5alpha Gal-L7E-VP64 pCMV5  
634 DH5alpha Gal-L7E half F-VP16 pCMV5  
635 DH5alpha Gal-L7E full F –VP16 pCMV5  
636 DH5alpha Gal-L7E no F -VP16 pCMV5  
638 DH5alpha KRAB-Gal-L7E pCMV5  
639 DH5alpha KRAB-Gal-ER pCMV5  
640 DH5alpha KRAB-Gal-7S pCMV5  
641 DH5alpha p65GalL7E pCMV5  
642 DH5alpha p65GalER pCMV5  
643 DH5alpha p65Gal7S pCMV5  
644 DH5alpha Gal-L7E-p65 pCMV5  
3125 DH5alpha p65-Gal-4S-EYFP pCMV5  
3126 DH5alpha p65-Gal-4S-YN pCMV5  
3127 DH5alpha p65-Gal-4S-YC pCMV5  
3128 DH5alpha EYFP-p65-Gal-4S pCMV5  
3129 DH5alpha YN-p65-Gal-4S pCMV5  
3130 DH5alpha YC-p65-Gal-4S pCMV5  
3131 DH5alpha YN-p65-Gal-L7E  
2392 DH5alpha Gal4SVP16 pCMV5  
2393 DH5alpha Gal5SVP16 pCMV5  
2394 DH5alpha Gal6SVP16 pCMV5  
2395 DH5alpha Gal7SVP16 pCMV5  
1162 DH5alpha KRAB-ER(1-595)-KRAB pCMV5  
1163 DH5alpha KRAB-7S(1-595)-KRAB pCMV5  
1164 DH5alpha KRAB-L7E(1-595)-KRAB pCMV5  
648 DH5alpha 2ERE-pS2-Luciferase pGL2  
1321 DH5alpha CMV-2ERE-pS2-Luciferase pGL2  
1115 DH5alpha galTATA-ERE-pS2-Luciferase pGL3  
2398 DH5alpha galTATA-Full7S(1-595) pGL3  
2399 DH5alpha Full7S(1-595) pCMV5  
2400 DH5alpha galTATA-KRAB-ER(1-595 G400V)-KRAB pCMV5  
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Chapter 3: Mammalian Screening System for Gene Switch Engineering 
3.1. Introduction 
The power of directed evolution as a protein engineering tool lies in its ability to link a large 
library of genotypes to individual phenotypes that can be screened or selected for. While there 
are a number of in vitro systems that can manage this task such as SELEX (1) or emulsion 
encapsulation (2), the simplest and most flexible method is to isolate each gene variant from the 
others within its own living host cell. One of the fundamental enabling technologies of the 
molecular biology revolution was the ability to ligate a gene into a small piece of DNA called a 
plasmid, and efficiently insert this into a bacterium and allow the cellular machinery to transcribe 
the gene into RNA and translate the RNA into a protein (3, 4, 5). Using these techniques and a 
screening system it is possible to isolate DNA sequences or proteins of interest from a library of 
variants. 
 
The characteristics of the bacteria E. coli and the yeast S. cerevisiae allow for straightforward 
library screening. Gene libraries can easily be constructed through restriction digestion and 
ligation of DNA into plasmids, followed by high efficiency transformation into bacteria by either 
heat shock or electroporation. While the transformation of yeast with ligation products is 
inefficient, libraries of up to 1010 plasmids can be constructed by introducing DNA fragments 
and taking advantage of the in vivo homologous recombination mechanisms active in yeast (6, 
7). The fast growth of both bacteria and yeast speeds the library screening process, and the 
plasmids are stably maintained through the use of selection markers, allowing for the isolation of 
individual clones. While multiple plasmids can be transformed into either E. coli or S. cerevisiae 
(8, 9), these can be reduced by lowering the amount of DNA transformed or the effects of the 
individual plasmids can be separated by plasmid isolation from promising clones followed by 
retransformation. 
 
However there are many applications where it is necessary to screen a library in mammalian 
cells. For screens affecting mammalian specific genes or signaling pathways, a mammalian cell 
based assay is usually required. More generally, many proteins require post-translational 
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modifications for correct function and these may vary between species. For example there are 
mammalian specific patterns of glycosylation that are essential for immune system function (10). 
 
Screening in mammalian cells presents multiple challenges. Standard methods of introducing 
DNA into mammalian cells in culture include calcium phosphate precipitation, electroporation, 
or complexing the DNA with a cationic lipid (lipofection) (11). The amount of DNA used for 
these processes is much greater than that used for bacterial and yeast transformation, and results 
in large numbers of plasmids introduced into each mammalian cell, up to 105 copies per cell 
under standard lipofection conditions for example (12). The large number of plasmids is in part 
required because once in the cytoplasm only a small fraction will actually reach the nucleus in 
order to be transcribed. This is not appropriate for library screening as the effect from any 
individual plasmid will be masked by the others also in the cell. Plasmids are also not usually 
stably maintained in mammalian cells, and will be steadily degraded after transfection. This, 
combined with the long cell cycle length of around 24 hours, means that individual clones cannot 
be isolated apart from rare events resulting from plasmid integration into the mammalian genome 
and requiring many weeks of selection. 
 
One method that does allow for mammalian screening involves the use of retroviral libraries. 
Retroviruses are a class of virus whose genome is a single stranded RNA molecule, that upon 
infection of a eukaryotic host is reverse transcribed into a DNA molecule that then integrates into 
the genome (13). Knowledge of the retroviral lifecycle and genome structure allowed the 
creation of engineered vectors that allow for the integration of a desired gene into the genome. 
By replacing the viral genes with a desired gene and using an engineered viral packaging cell 
line, virus is produced that allows for the integration of a gene of interest but that does not have 
the ability to further replicate. This system allows for the multiplicity of infection to be 
controlled such that a single integration event per mammalian cell is achievable. Retroviral 
approaches have been used for many applications including screening cDNA expression libraries 
for genes causing a particular phenotype (14), genome-scale RNAi gene knockdown screens 
(15), enzyme engineering (16), and engineering of zinc finger artificial transcription factors (17). 
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Another approach for mammalian library screening is to use a technique called protoplast fusion, 
where whole cells are stimulated to fuse together to form a hybrid cell. Spontaneous cell 
hybridization has been observed in mammalian cell culture experiments (18) but many 
organisms have a strong wall around their cell membrane that would prevent such occurrences. 
Protoplasts are the result of removing the rigid cell wall from bacterial, fungal, or plant cells, 
leaving the cellular contents surrounded simply by the lipid bilayer membrane (19). Research 
showed the feasibility of intra- and inter-species protoplast fusion methods in plants (20), and the 
stimulatory effect of the addition of high concentrations of polyethylene glycol (PEG) (21). The 
method was demonstrated in bacteria (22, 23), and was developed as a method to introduce 
genetic material from E. coli into mammalian cells in a clonal manner (24). In addition to its use 
in strain development and basic research, protoplast fusion has been used to clone genes from 
cDNA libraries (25, 26), and to screen libraries for active variants (27, 28). 
 
The established method for engineering ligand binding domain controlled gene switches used in 
the Zhao laboratory was a yeast two-hybrid strategy (29). This relies on the transcription of a 
GAL4 response element controlled histidine biosynthesis gene, allowing growth of the yeast in 
media lacking histidine. Transcription is promoted by the recruitment of a GAL4DBD-ERαLBD 
construct associated in a ligand dependent manner with a steroid receptor coactivator 1 / 
GAL4AD fusion construct. The level of reporter gene production, and hence growth, is 
determined by how well the ligand of interest binds to the particular LBD mutant present in the 
cell. A saturation mutagenesis approach was systematically used to identify variants at amino 
acid positions known to affect ligand binding. 
 
As discussed in Chapter 2, the ligand/LBD pairs L9/L7E and DHB/7S are not ideal for use as a 
gene switch in mammalian systems. The ligands are not approved for use in humans, preventing 
any downstream gene therapy applications, and are not easily available commercially. Also, the 
final engineered ligand binding domains showed poor performance with alternate DNA binding 
domains and activation domains. Partly to address some of these issues, Victor Gonzalez from 
the Zhao and Katzenellenbogen laboratories had used the yeast two-hybrid screening strategy 
(29) to engineer the ERα LBD for increased specificity towards hexylresorcinol. The mutations 
found were H524P, M421G, M343C, L391V, G521T, F337L, and L479R with the most sensitive 
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variant being the fourth round mutant with an EC50 of 36.6 nM to hexylresorcinol and 800 nM to 
estradiol, with the sixth round mutant showing an EC50 of 91.1 nM to hexylresorcinol and no 
response to estradiol up to 10-5 M (30). 
 
Hexylresorcinol was chosen as a target ligand for a number of reasons. The compound (Figure 
3.1) is a doubly hydroxylated benzene with a 6-carbon alkyl chain attached. When present at 
levels of 10 µM it has a low level of agonistic activity toward the estrogen receptor α ligand 
binding domain when measured by a yeast two-hybrid assay (Figure 3.2), although estrogenic 
effects at lower concentrations have been reported (31). This initial agonist activity allows the 
yeast two-hybrid screening approach to be used to engineer increased sensitivity. The compound 
has been recognized for many decades as both non-toxic to humans and possessing antimicrobial 
activities (32). It shows anesthetic activity and is an ingredient in throat lozenges (33). By acting 
as an inhibitor of the enzyme polyphenol oxidase, it can be used to prevent browning of fruit and 
crustaceans in the food industry (34, 35). The low toxicity and low activity toward the estrogen 
receptor make this compound an attractive ligand for use as a gene switch activator. 
 
Figure 3.1. Hexylresorcinol and 17β-estradiol ligands. 
 
A number of results had suggested that a mammalian screening method could have advantages 
over the yeast two-hybrid approach. The yeast system is based on the well characterized GAL4 
DNA binding domain and response elements, whereas it is desirable to use the gene switch to 
target any given promoter. The need to change the DBD after engineering ligand specificity 
opens the door to unappreciated LBD-DBD interdomain contacts changing the performance of 
the gene switch. The mammalian intracellular milieu consists of many proteins not present in 
yeast that could interact in unknown ways with the gene switch. From a functional perspective, 
as seen in Chapter 1, the engineered ligand binding domains do not always perform as 
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anticipated upon transfer into mammalian cells. It was also observed that transfer of the 
hexylresorcinol engineered LBDs into mammalian gene switches gave a reduced sensitivity to 
ligand (Figure 3.3). If the engineering of the gene switch could take place in a context as close as 
possible to the desired use, unexpected results could be avoided. This would mean engineering in 
mammalian cells, and starting with the complete construct design including activation domain 
and DNA binding domain to target the gene of interest. 
 
The goal of this chapter was therefore to investigate the utility of protoplast fusion as a means of 
screening in mammalian cells, and attempt to engineer a hexylresorcinol responsive gene switch 
targeting the VEGF-A gene (see Chapter 4). The previously engineered hexylresorcinol 
responsive ligand binding domains were shown to have a reduced sensitivity when cloned and 
expressed in mammalian cells. The protoplast method was shown to be capable of introducing 
plasmid into HeLa cells, and plasmid could be recovered back from them. A GAL response 
element controlled EGFP gene was created and integrated into HeLa cells and could be induced 
by gene switches containing GAL DNA binding domains. The VEGF-A promoter did not exhibit 
reliable induction of the EGFP gene, despite multiple constructs and positive feedback loops 
being tested. Although some initial results showed promise for the protoplast fusion screening 
using the GAL-responsive cell line, under library screening conditions the system was not able to 
recover a known active mutant. A fluorescent sensor construct was tested using protoplast fusion 
but this also was unable to retrieve the known mutant, leading to the determination that gene 
switch engineering using this approach was not feasible. Returning to the yeast two-hybrid 
screening system, three rounds of engineering were performed and yielded variants that showed 
increased sensitivity to hexylresorcinol, but again when these mutants were cloned into the 
mammalian gene switches a loss of sensitivity was observed. 
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3.2. Results and Discussion 
3.2.1. Rationale for Developing a Mammalian Screening System 
The utility of the hexylresorcinol/LBD pairs was evaluated for use as a gene switch. The 
sensitivity of the 4th, 5th, and 6th round mutants (named C2-4S, C2-5S, and C2-6E) was 
confirmed using the yeast growth assay (Figure 3.2). The LBDs were recloned into mammalian 
expression constructs in three forms: within the context of the full length estrogen receptor, 
within the gene switch context p65-Gal-LBD, and also directly recloned without modification. 
When analyzed for their ability to show ligand induced transcription from a luciferase reporter 
gene in HeLa cells, they revealed a loss of sensitivity (Figure 3.3). In all cases at least a ten-fold 
reduction in sensitivity to hexylresorcinol was observed, showing that these LBDs were not 
suitable for use as a gene switch. These findings spurred the consideration of alternative 
approaches to engineering gene switches for use in mammalian cells. (Book 4 pg 169-205) 
 
 
 
Figure 3.2. Response of engineered ligand binding domains to hexylresorcinol. Yeast strains containing 
the 4th, 5th, and 6th round engineered mutants were grown in the presence of hexylresorcinol (0 = no 
ligand, H9-H5 are 10-9 M to 10-5 M concentrations of hexylresorcinol) or estradiol (0 = no ligand, E10-E5 
are 10-10 M to 10-5 M concentrations of estradiol). Growth was monitored by determining the optical 
density at 600 nm. 
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Figure 3.3. Loss of sensitivity of hexylresorcinol engineered LBDs in mammalian HeLa cells. (a) LBDs 
cloned into the full length ERα context activating a pS2-ERE-luciferase reporter in response to 
hexylresorcinol. (b) LBDs cloned with a p65 activation domain and Gal4 DNA binding domain activating 
a GalTATA-luciferase reporter. Shown for comparison is the 4th round DHB mutant (p65Gal4S) induced 
by the DHB ligand. (c) The yeast engineering constructs recloned without modification activating a 
GalTATA-luciferase reporter. 
 
3.2.2. Protoplast Fusion as a Means of Introducing Plasmids Into Mammalian Cells 
An engineering approach using mammalian cells was conceived (Figure 3.4). The desired gene 
switch would be cloned in E. coli, allowing for the creation of libraries of LBD variants. These 
would be grown in culture, converted to protoplasts, and fused to a HeLa cell line containing an 
integrated EGFP gene under the control of the promoter of interest. Expression of the gene 
switch would follow the transfer of the plasmid into the nucleus, and its activity would be 
stimulated by the addition of ligand. The gene switch would cause expression of the EGFP gene, 
allowing isolation of that HeLa cell by fluorescence activated cell sorting (FACS). The plasmid 
encoding the active gene switch would then be isolated from the HeLa cell, transformed back 
into E. coli for verification or for a further round of protoplast fusion. This approach would have 
an advantage over a retroviral based library since it would have fewer steps (no retrovirus 
production step after cloning the library) and the active clones would be directly recovered as 
plasmids from the HeLa cells, as opposed to the PCR recovery required to retrieve a 
chromosomally integrated construct. The method was investigated with the assistance of Jing 
Liang (Zhao Laboratory). 
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Figure 3.4. Overview of the proposed mammalian based protoplast fusion screening method for gene 
switch engineering. 
 
As a first step toward developing protoplast fusion for our library screening system, it was 
necessary to show that it could introduce plasmid into the HeLa cells efficiently. The codon 
optimized fluorescent protein EGFP was cloned into the expression vector pCMV5, and shown 
by lipofection to be expressed in HeLa cells (Figure 3.5a). The percentage of fluorescent cells 
was dependent on the amount of plasmid introduced, and was typically between 50-80%. After 
some optimization, protoplast fusion was used to reliably introduce the EGFP plasmid into the 
HeLa cells (Figure 3.5b). Here the proportion of fluorescent cells was typically 30-40% of the 
population. One well of a 6-well plate contains approximately one million HeLa cells at 
confluent growth. If protoplast fusion is performed at 50% confluency, one 6-well plate should 
give around one million successfully transformed cells which is judged sufficient for library 
screening. (Book 5 pg 121, 175-183) 
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Figure 3.5. Expression of EGFP in HeLa cells monitored by flow cytometry. (a) EGFP plasmid 
introduced via lipofection. (b) EGFP plasmid introduced by protoplast fusion. 
 
3.2.3. Construction of an EGFP Integrated HeLa Reporter Cell Line 
Having shown that EGFP can be successfully introduced into HeLa and monitored by flow 
cytometry, the next requirement of the screening system was to construct a stable cell line that 
contained an integrated EGFP reporter gene. Two reporter genes were constructed in parallel. As 
a control, a GalTATA-EGFP construct was made to take advantage of the well performing and 
highly inducible synthetic promoter. As an endogenous target, we had chosen to regulate the 
Vascular Endothelial Growth Factor A gene so a VEGF-A-EGFP construct was also made. 
Testing of these reporter genes was performed by lipofection prior to the lengthy process of 
integration.  
 
The GalTATA-EGFP reporter performed well. As shown in Figure 3.6a, the reporter exhibited 
only a slight basal expression that increased fluorescence above the level of the β-galactosidase 
non-fluorescent control. When the Gal targeting gene switch p65-GAL-4S was also present, 
there was no induction in the absence of DHB ligand, but around a ten-fold increase in the 
number of fluorescent cells when in the presence of DHB, and a 50-fold increase in the 
population fluorescence. 
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The VEGF-A-EGFP reporter did not show desirable induction characteristics (Figure 3.6b). A 
number of conditions were tested for their ability to activate this reporter. A constitutively active 
transcription factor, nlsVZ8p65, was constructed using an engineered zinc finger DNA binding 
domain called VZ8 (36) in conjunction with a nuclear localization sequence (nls) and the 
activation domain from the transcription factor p65. A ligand controlled gene switch was also 
created, p65(451-551)VZ8-4S, with a shorter region of the p65 activation domain and the 
addition of the 4th round DHB activated ERα LBD. As a non gene switch control, the addition of 
100 µM cobalt chloride was used since this compound mimics the effect of hypoxia, leading to 
VEGF-A induction. The ligand-dependent gene switch had little effect on the expression of 
EGFP, and the constitutive switch caused only a slight increase. The cobalt chloride treatment 
gave the highest induction of EGFP, but this was only a 4 or 5 fold increase in either fluorescent 
cells or population fluorescence. 
 
Since the GalTATA reporter performed well, it was stably inserted into the HeLa genome by 
retroviral integration. The GalTATA-EGFP segment was cloned into the retroviral vector 
pLHCX, lipofected into the packaging line GP2-293, and virus particles were collected and 
exposed to HeLa cells. Stable transformants were isolated by selection with hygromycin, and 
with the help of Jing Liang, were expanded and screened for reporter gene induction. A number 
of independent cell lines were isolated that showed low basal fluorescence and good induction 
upon the introduction of a constitutively acting artificial transcription factor GALp65 by either 
lipofection (Figure 3.7a) or protoplast fusion (Figure 3.7b). (Book 5 pg158-220) 
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Figure 3.6. Activity of EGFP reporters introduced to HeLa cells by lipofection. (a) HeLa cells were 
transfected with the non-fluorescent β-galactosidase (bGal), the GalTATA-EGFP reporter plasmid, the 
reporter plasmid plus the DHB controlled gene switch p65Gal4S, or the reporter plus gene switch plus 
DHB ligand. (b) HeLa cells transfected with the β-galactosidase gene, the VEGF-A-EGFP reporter gene, 
the reporter gene plus cobalt chloride (CoCl2), the reporter gene plus the gene switch p65(451-551)VZ8-
4S, or the reporter gene plus the gene switch plus DHB. 
 
 
 
Figure 3.7. Induction of fluorescence in the stable GalTATA-EGFP HeLa cell line. (a) The GalTATA-
EGFP cell line was lipofected with the β-galactosidase gene (GalTATA-EGFP Line) or with the 
constitutively acting GALp65 construct. (b) Induction of fluorescence within the GalTATA-EGFP cell 
line upon introduction of GALp65 by protoplast fusion. 
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3.2.4. VEGF-A Reporter Constructs 
A number of different reporter constructs were investigated to find a functional VEGF-A 
reporter that could be used for mammalian screening. Due to the low induction of fluorescent 
signal from the VEGF-A promoter, several constructs were made to test the effect of signal 
amplification, as summarized in Table 3.1. The cascade design takes advantage of the well 
performing GalTATA-EGFP reporter by attempting to use a ligand controlled VEGF-A targeting 
gene switch to induce expression of the GALp65 construct from a VEGF-A promoter. VEGF-A-
mVenus-nlsVZ8p65 forms a VEGF autoinduction loop by using a fluorescent mVenus tag 
attached to a constitutive VEGF-A targeting construct (nlsVZ8p65) under control of a VEGF-A 
promoter. VEGF-A-mVenus-GALp65 adds a fluorescently tagged transcription factor to the 
cascade scheme, GalTATA-mVenus-galp65 forms a fluorescent autoinduction loop via the 
GalTATA promoter. When expressed in HeLa cells and analyzed by flow cytometry, none of the 
combinations tested gave desirable results. The cascade system showed induction by cobalt 
chloride but not the gene switch (Figure 3.8). The GalTATA-mVenus-GALp65 gave a lower 
signal than the gtEGFP reporter and a decrease when ligand was added. Neither VEGF-A-
mVenus-NLSvz8p65 nor VEGF-A-mVenus-GALp65 conditions gave a fluorescent signal, 
suggesting that either transcription or translation of the N-terminal fluorescent protein from the 
VEGF-A promoter is not effective. 
 
To test transcription from the VEGF-A reporters, reverse transcription PCR was performed. RNA 
was isolated from HeLa cells lipofected with the gene switch p65GAL4S and the reporters 
GalTATA-pGL3 (luciferase), VEGF-A-pGL3 (luciferase), GalTATA-EGFP, and VEGF-A-EGFP. 
RT-PCR was performed to measure the mRNA levels for the luciferase and EGFP, and both 
cases showed good induction from the GalTATA promoter but very low levels without noticeable 
induction for the VEGF-A promoter (Figure 3.9). This suggests that the difficulties in developing 
a good reporter are partly due to a low level of transcription induced from the VEGF-A 
promoter.(Book 5 pg 250 – Book 6 pg 123) 
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Table 3.1. VEGF-A reporter amplification strategy plasmids 
Cascade VEGFa Autoinduction Fluorescent GALp65 GalTATA Autoinduction 
P65-4S-nlsVZ8-pCMV5 
VEGFa-GALp65 
GalTATA-EGFP 
P65-4S-nlsVZ8-pCMV5 
VEGFa- mVenus-nlsVZ8p65 P65-4S-nlsVZ8-pCMV5 
VEGFa- mVenus-GALp65 
GalTATA-EGFP 
P65-4S-nlsVZ8-pCMV5 
VEGFa-GALp65 
GalTATA-mVenus -GALp65 
 
 
 
Figure 3.8. Cascade system for VEGFa reporter induction. 
 
 
 
Figure 3.9. RT-PCR from reporter constructs. (a) EGFP mRNA, lane 1 is a DNA ladder, lanes 2 and 3 
are uninduced and induced expression from GalTATA-EGFP, lanes 4 and 5 are negative controls, lanes 6 
and 7 are uninduced and induced expression from VEGF-A-EGFP. (b) Luciferase mRNA, lane 1 is a 
DNA ladder, lanes 2 and 3 are uninduced and induced expression from GalTATA-pGL3, lanes 4 and 5 are 
uninduced and induced expression from VEGF-A-pGL3. 
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3.2.5. Library Screening Using Protoplast Fusion in the GalTATA-EGFP Cell Line 
Due to the lack of a highly functional VEGF-A reporter construct, it was decided to attempt 
screening using protoplast fusion with the GalTATA-EGFP integrated cell line. This required the 
use of the GAL4 DNA binding domain gene switch. As an initial test of the screening process, I 
attempted to enrich the wild type LBD present in a 1:10 library ratio of p65GALER:p65GAL4S. 
As seen in Figure 3.10, the protoplast fusion was successful with the constitutively acting control 
plasmid GALp65, giving an obvious 20 % of the population with increased fluorescence. The 
ligand controlled gene switch gave a long low tail with about 5 % of cells having increased 
fluorescence upon 100 nM DHB induction. The p65GALER construct was responsible for a 
small increase in fluorescence upon the addition of 100 nM estradiol. The top 4000 fluorescent 
cells were collected and their plasmids were isolated and transformed into E. coli. Colonies were 
recovered at a level of 1 colony per 4-5 fluorescent HeLa cells collected by FACS. Plasmids 
were isolated from ten colonies and digested with a diagnostic restriction enzyme BsrGI. All 
clones produced a digestion pattern characteristic of either the ER or 4S construct, and revealed 
that the DHB exposed cells contained a ratio of one ER and nine 4S LBDs, which was the same 
as the initial library. Of the clones isolated from the estradiol exposed cells, two contained the 
ER LBD, indicating a slight enrichment from the initial library. 
 
This experiment was repeated, and cells were collected by FACS into a highly fluorescent pool 
(500 cells), or a moderate fluorescent pool (1000 cells). When isolated clones were analyzed by 
restriction digestion, unsorted cells gave 0/10 ER LBDs, the moderate pool gave 2/10 ER, and 
the highly fluorescent cells gave 4/10 ER. These results indicated that successful enrichment was 
possible from a low complexity library. 
 
To determine the effectiveness of the screening approach under more realistic conditions, I 
attempted to isolate the first round DHB mutant known from the yeast two-hybrid engineering 
(A350M, see Chapter 2). A saturation mutagenesis library was constructed at position 350 in the 
gene switch template p65GAL-LBD. This plasmid library was diluted with an excess of plasmid 
p65GAL-ER, containing the wild type ligand binding domain such that the A350M mutant was 
expected to be present at a ratio of 1:1000 of the entire library. Protoplasts were made, fused to 
the GalTATA-EGFP cells, and exposed to 50 nM DHB for two days. The cells underwent FACS 
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and the top 1 % of cells was collected, and plasmids were isolated from these 2000 cells. Of four 
clones retransformed into E. coli, one gave poor sequence, and the remaining three were wild 
type. A second round of enrichment using protoplast fusion was performed using the plasmid 
library isolated from the first round. Again, four clones were sequenced but only wild type 
sequence was observed. These results showed that under realistic library conditions, the 
protoplast fusion method did not effectively enrich functional gene switch clones. (Book 6 pg 
157 – Book 7 pg 5, 102-126) 
 
 
Figure 3.10. Initial trial of protoplast fusion based screening in GalTATA-EGFP cell line. Shown is the 
flow cytometry data of the unfused cell line, and protoplast fusion conditions with the constitutive 
GALp65, the p65GALER/p65GAL4S library induced by DHB, and the p65GALER/p65GAL4S library 
induced with estradiol (E2). 
 
3.2.6. Library Screening Using Protoplast Fusion With a Fluorescent Sensor Construct 
The fluorescent sensor construct discussed in Chapter 5 was investigated as a screening system 
for mammalian cells. These constructs consist of the ERα ligand binding domain (amino acids 
312-595) flanked by a split fluorescent protein (mVenus), and show an increase in fluorescence 
upon the binding of a ligand. Although the construct is not a gene switch (it has no DNA binding 
domain to influence gene transcription), it was reasoned that it may provide an alternative means 
of engineering the ligand binding domain to respond to new ligands, by selecting for variants that 
show an increased fluorescence with the ligand of interest. 
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A number of mutant ligand binding domains were cloned into the sensor construct format, to 
analyze whether different fluorescent sensor LBDs could recapitulate the binding properties as 
seen in yeast or mammalian cells. As seen in Figure 3.11a, the 4S DHB responsive mutant shows 
induction of fluorescence in the presence of 10-7 M DHB, but no response to a similar level of 
estradiol. This replicates the dose response for this mutant in the yeast two-hybrid assay (see 
Figure 2.3b for comparison). Interestingly, when the 7th round DHB and L9 responsive mutants 
(7S and L7E) were cloned as fluorescent sensors, they show the high basal activity and low 
induction that were observed with their gene switch activity in mammalian cells (Figure 3.11b). 
The sensor constructs therefore convey useful information about the possible performance of the 
LBDs for gene switch purposes, and screening by protoplast fusion was performed. (Book 7 pg 
85-126) 
 
 
Figure 3.11. Performance of fluorescent sensors containing engineered ligand binding domains. (a) 
Sensor containing the 4S DHB mutant with a DHB and estradiol ligand titration. (b) Sensor constructs 
containing the wild type ERα LBD, or the 7th round DHB (7S) or L9 (L7E) mutants in the absence or 
presence of ligand. 
 
Again it was decided to try to isolate the mutant A350M, known to show increased sensitivity to 
DHB. Using the wild type sensor construct as a scaffold, saturation mutagenesis libraries were 
made for the 19 sites targeted for our gene switch engineering studies (including position 350). 
Protoplasts were made for either an all position library or only position 350 library, and these 
were fused into HeLa cells, treated with DHB, and underwent FACS (Figure 3.12a). Plasmids 
isolated from the top 1 % of cells were recovered into DH5α cells and four colonies were 
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miniprepped and sequenced. None of the colonies were A350M, but 2 of the four colonies from 
the 350 library were A350L, as was one of the four colonies from the all 19 position library.  
 
The A350L mutant was cloned into the p65Gal-LBD gene switch context and tested for its 
ability to activate a luciferase reporter gene in mammalian cells. As seen in Figure 3.13, the 
A350L mutant did show an increase in DHB sensitivity. So the protoplast fusion method 
successfully pulled out a functional mutant. However, the sensitivity of the A350M mutant was 
higher so this would have been expected to be isolated in the screen. There are more leucines 
coded for by the NNS saturation mutagenesis codon (CUC, CUG, and UUG) than the single 
AUG methionine, so library bias may have contributed to the failure to retrieve the expected 
mutant. Also, only a small number of clones were sequenced in this initial trial. 
 
 
Figure 3.12. FACS on the sensor protoplast fusion libraries. (a) The first protoplast fusion screening. For 
clarity, only shown is the data for the position 350 library. The three curves show the uninduced fused 
HeLa cells, induction with 100 nM estradiol, and induction with 50 nM DHB. (b) The second sensor 
construct protoplast fusion using a library of all 19 sites with uninduced, and induction with 10 nM DHB. 
In both trials the top 1% of cells were collected for plasmid isolation. 
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Figure 3.13. Luciferase reporter gene activation by the A350 mutants cloned into the mammalian gene 
switch context p65Gal-LBD. Data is normalized such that the no ligand WT value equaled 1, and is the 
average and standard deviation of duplicate samples. 
 
Encouraged by the isolation of a mutant more sensitive to DHB than the wild type LBD, another 
protoplast fusion attempt was performed using the fluorescent sensor constructs (Figure 3.12b). 
A high level of basal fluorescence was observed and a lack of induction with DHB ligand. 
Although the top 1% of cells were collected, none of the 10 plasmids sequenced from these were 
either the A350M or A350L mutants previously identified. 
 
Although some promising results were obtained, the protoplast fusion screening system was 
determined to be unreliable for gene switch engineering. Under library screening conditions, 
both the gene switch approach and the fluorescent sensor construct approach failed to retrieve the 
known A350M mutant responsive to DHB. For the gene switch approach, a number of steps are 
necessary for induction. First, the plasmid must be introduced to the reporter line, enough copies 
need to reach the nucleus to allow transcription of the gene switch for subsequent translation. 
The gene switch then requires activation by ligand and induction of the reporter EGFP gene to 
allow isolation of the HeLa cell by FACS. At this point, enough of the plasmid must still remain 
in the HeLa cell for isolation. At each of these steps, there is a loss of efficiency that reduces the 
performance of the system. The sensor construct allows for a direct readout of fluorescence, 
saving one transcription and translation step, however, significant basal signal was observed and 
a distinct induced population was not evident. Protoplast fusion has been used previously to 
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successfully screen libraries of arginine rich RNA binding proteins (27), and for internal 
ribosome entry sites (28). In both of these examples, the elements under selection were not 
ligand activated, as is the case of the gene switch. The requirement for ligand activation does 
decrease the number of induced cells, so this was an extra hurdle that the gene switch 
engineering faced with protoplast fusion. The amount of plasmid mutation after recovery from 
the HeLa cells was higher than expected based on previous reports, suggesting only around 1 % 
of plasmids recovered from mammalian cells were defective (37). All these factors seemed to 
push the method beyond its limits, resulting in poor performance. 
 
3.2.7. Yeast Two-Hybrid Screening for the Hexylresorcinol Ligand 
After it was determined that the protoplast fusion method was not feasible for gene switch 
engineering, the yeast two-hybrid method was resumed in another attempt to generate a 
hexylresorcinol responsive ERα LBD. Three rounds of stepwise site saturation mutagenesis were 
applied to 19 sites of the wild type hERα-LBD (WT): 343, 346, 347, 349, 350, 383, 384, 387, 
388, 391, 404, 421, 424, 425, 428, 521, 524, 525, and 528. The results from yeast are shown in 
Figure 3.14 and Table 3.2. Round 1 produced the mutant G524T, round 2 yielded A350M, and 
the third round gave L384M. Each round produced an increase in the sensitivity to 
hexylresorcinol, a 94-fold improvement at round 3 over the wild type starting point, although the 
third round mutant achieved this sensitivity at a cost of increased ligand independent basal 
activity. Sensitivity to estradiol decreased at the first and second rounds, but then increased at the 
third round. 
 
Figure 3.14. Growth of yeast strains carrying the engineered LBDs in response to (a) hexylresorcinol, and 
(b) estradiol (E2). 
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Table 3.2. Sensitivity of the mutants to hexylresorcinol and estradiol. The values are the mean and 
standard error of the mean expressed in nM based on the yeast growth curves. 
Clone  Hexylresorcinol EC50 E2 EC50 
WT 
 9300 (780) 0.075 (0.0063) 
Round 1 (G524T) 1100 (240) 1.7 (0.25) 
Round 2 (G524T/A350M) 410 (37) 78 (7.9) 
Round 3 (G524T/A350M/L384M) 99 (5.7) 9.1 (0.32) 
 
At this point, the engineered ligand binding domains were cloned into the gene switch context 
p65-GAL-LBD for testing in HeLa cells. Luciferase assays were performed to measure the 
induction of a GalTATA-Luciferase reporter gene and the results are shown in Figure 3.15. The 
second round mutant was seen to be the most sensitive to hexylresorcinol. However, a decrease 
in sensitivity as compared to the yeast growth curve was observed, as had been the case with the 
original variants engineered by Victor Gonzalez. It was not until micromolar concentrations of 
hexylresorcinol were present that any induction was observed, with only a four-fold increase 
observed for the best mutant. At 10 µM, the round 2 mutant gave over twenty-fold induction. 
However, at this high concentration of ligand, even the wild type LBD responded with a nine-
fold induction (Figure 3.15a). Consistent with a lowered sensitivity in the HeLa cells, the 
response to estradiol was also reduced (Figure 3.15b) (Book 7 pg 130-158, Book 8 pg 1-56) 
 
Figure 3.15. Mammalian luciferase using the engineered hexylresorcinol LBDs cloned with p65 
activation domain and the Gal4 DNA binding domain. Shown is the response to (a) hexylresorcinol, and 
(b) estradiol. 
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3.3. Conclusions and Outlook 
Despite individual steps of the protoplast fusion method were performing adequately, the overall 
method was not feasible for engineering gene switches in mammalian cells. The low level of 
induction was seen to be a problem, both in comparing the highly inducible synthetic GalTATA 
promoter to the endogenous VEGF-A promoter and also when comparing the activity of a 
constitutive switch to one containing a ligand binding domain. While not appropriate for the 
current engineering goals, protoplast fusion could conceivably be used for directed evolution of 
other targets that require expression in mammalian cells. 
 
The loss of sensitivity that was observed with the newly engineered hexylresorcinol responsive 
LBDs upon their transfer into mammalian cells highlights that a functional mammalian screening 
method is still desirable. A retroviral screening system could be investigated. While this would 
involve a few extra steps for the creation of the library, once integrated into mammalian cells, the 
gene switch would be stable for as long a screening time as is needed. This could have the 
advantage of allowing an initial FACS screen to remove constitutively active mutants, followed 
by a second screen for ligand inducible mutants. 
 
3.4. Materials and Methods 
3.4.1. Reagents 
DNA polymerase, restriction enzymes, and T4 DNA ligase were from New England Biolabs 
(Beverly, MA). Chemicals were from Sigma-Aldrich (Carlsbad, CA). Media components were 
from BD Biosciences (San Jose, CA), and premixed synthetic complete amino acid dropout 
mixes were from MP Biomedicals (Irvine, CA) or Sigma-Aldrich (Carlsbad, CA). Cell culture 
media were from the UIUC cell media facility (Urbana, IL). Lipofectamine 2000 was from 
Invitrogen (Carlsbad, CA). The DHB ligand was synthesized by Victor Gonzalez (Urbana, IL). 
DNA isolation and miniprep kits were from Qiagen (Valencia, CA), and yeast miniprep kits were 
from Zymo Research (Orange, CA). 
 
3.4.2. Cloning of Constructs 
Standard molecular biology techniques were used to create the constructs used in these 
experiments (Table 3.3). The VEGF-A promoter was amplified by PCR from human genomic 
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DNA and cloned into the luciferase vector pGL3 (Promega, Madison WI) using the KpnI and 
NcoI sites. Gene switches were cloned into the mammalian expression vector pCMV5. 
 
Table 3.3. Constructs used in this work 
HZ Genotype Plasmid Details 
3243 DH5alpha C2-4S Full ER pCMV5  
3244 DH5alpha C2-5S Full ER pCMV5  
3245 DH5alpha C2-6E Full ER pCMV5  
3246 DH5alpha p65GALC2-4S pCMV5  
3247 DH5alpha p65GALC2-5S pCMV5  
3248 DH5alpha p65GALC2-6E pCMV5  
3249 DH5alpha GALC2-4S pCMV5  
3250 DH5alpha GALC2-5S pCMV5  
3251 DH5alpha GALC2-6E pCMV5  
1766 DH5alpha EGFP pCMV5  
2017 DH5alpha GalTATA-EGFP pGL3  
2020 DH5alpha VEGFa-EGFP pGL3  
3252 DH5alpha p65GAL4S pCMV5  
2021 DH5alpha nlsVZ8p65 pCMV5  
1875 DH5alpha p65(451-551)VZ8-4S pCMV5  
3253 DH5alpha GALp65 pCMV5  
613 DH5alpha GalTATA pGL3  
3254 DH5alpha P65-4S-nlsVZ8-pCMV5  
2024 DH5alpha VEGFa-GALp65  
3255 DH5alpha VEGFa- mVenus-nlsVZ8p65  
3256 DH5alpha VEGFa- mVenus-GALp65  
3257 DH5alpha GalTATA-mVenus -GALp65  
642 DH5alpha p65GALER pCMV5  
2243 DH5alpha Vn-ER312-595-Vc pCMV5  
3240 DH5alpha Vn-4S-Vc pCMV5  
3241 DH5alpha Vn-7S-Vc pCMV5  
3242 DH5alpha Vn-L7E-Vc pCMV5  
3258 DH5alpha p65GAL-A350L pCMV5  
3259 DH5alpha p65GAL-A350M pCMV5  
3260 DH5alpha p65GAL-Round1 pCMV5 G524T 
3261 DH5alpha p65GAL-Round2 pCMV5 G524T/A350M 
3262 DH5alpha p65GAL-Round3 pCMV5 G524T/A350M/L384M 
886 YRG2-SRC ER pBD Gal4-CAM  
3263 YRG2-SRC Round1 pBD Gal4-CAM G524T 
3264 YRG2-SRC Round2 pBD Gal4-CAM G524T/A350M 
3265 YRG2-SRC Round3 pBD Gal4-CAM G524T/A350M/L384M 
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3.4.3. Cell Culture 
HeLa cells were grown in minimal essential medium (MEM) plus 1 mM sodium pyruvate, and 
10% fetal bovine serum (FBS) (UIUC Cell Media Facility, Urbana, IL) at 37 °C with 5% carbon 
dioxide. When cells were 80% confluent, they were trypsinized and split into 24-well plates with 
MEM media plus 1 mM sodium pyruvate, and 5% charcoal dextran stripped calf serum (UIUC 
Cell Media Facility). Cells were grown for 24 hours until they were over 90% confluent and 
transfected using 1.5 µL lipofectamine 2000 (Invitrogen, Carlsbad CA), 100 ng β-galactosidase 
gene expression plasmid, 690 ng luciferase reporter gene expression plasmid, and 10 ng of the 
relevant gene switch plasmids per well. After four hours, the media was changed to the MEM 
media plus 1 mM sodium pyruvate, and 5% charcoal dextran stripped calf serum, plus estradiol 
or hexylresorcinol ligand. Cells were incubated for a further 24 hours, then lysed and assayed for 
the luciferase activity using the Luciferase Assay System (Promega, Madison WI). Luciferase 
levels were normalized to β-galactosidase expression. 
 
3.4.4. Stable Cell Line Creation  
The procedures outlined in the “Retroviral gene expression and user manual”, protocol PT3132-1 
(Clontech, Mountain View, CA) were followed. The GalTATA-EGFP and VEGF-A-EGFP 
constructs were cloned into the retroviral vector pLHCX (Clontech, Mountain View, CA). 4 µg 
of the plasmid was lipofected using lipofectamine 2000 with 4 µg of pVSVG plasmid into the 
retroviral packaging line GP2-293 (grown in DMEM/high glucose/2 mM L-glutamine/1 mM 
sodium pyruvate/10 % FBS) in a 60 mm plate. After five hours, the media was replaced and the 
cells were incubated for 48-72 hours and then the media containing retrovirus was collected, 
filtered, and stored at -80 °C. Different amounts of retrovirus, from 20 µL to 1500 µL, were 
added to HeLa cells in the presence of 8 µg/mL polybrene and incubated for 24 hours. The 
media was changed and cells incubated for 24 hours before changing the media and including 
200 µg/mL hygromycin. Cells were grown under antibiotic selection for two weeks, after which 
colonies were isolated with cloning rings, trypsinized, and transferred to individual wells of a 24 
well plate. Cell lines were expanded under selection into wells of a 12 well plate, then a 6 well 
plate, then into a T25 flask. At this point, cells were assayed for reporter gene activity and well 
performing cell lines were expanded for use and storage in liquid nitrogen. 
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3.4.5. Protoplast Fusion 
Protoplast fusion procedures were adapted from published methods (27, 38). Generally, 50 ng of 
expression plasmid was electroporated into DH5α E. coli cells. The cells were incubated at 37 
°C in Luria Broth (LB) media for 1 h and then transferred into a flask containing 50 mL LB and 
100 µg/mL ampicillin. The flask was incubated at 37 °C with shaking for 4-6 h until the optical 
density at 600 nm reached 0.8 at which point chloramphenicol was added to a concentration of 
200 µg/mL. After a 12-16 h incubation to amplify the plasmid copy number, the cells were 
pelleted by centrifugation and resuspended in 3 mL of ice-cold 20 % sucrose / 50 mM Tris-HCl 
pH8. 600 µL of 10 mg/mL lysozyme in 0.25 M Tris-HCl pH 8 was added to the cell solution and 
incubated on ice for 5 min. 1200 µL of 0.25 M EDTA pH 8 was added, followed by a 5 min 
incubation on ice. 1200 µL of 50 mM Tris-HCl pH 8 was added and incubated for at 37 °C for 
10 min to generate the protoplasts. At this point, 1 µL of the solution was placed on a 
microscope slide, covered with a cover slip, and observed by phase contrast light microscopy. A 
good preparation had at least 80 % individual spherical protoplasts visible. If the population 
showed a high proportion of oblong bacteria (indicating intact cell walls), the solution was 
incubated for another 5-10 min at 37 °C until most were converted into protoplasts. The 
protoplast solution was resuspended by adding 20 mL of ice-cold 10 % sucrose / 10 mM MgCl2 
in MEM media, slowly and with gentle mixing to prevent osmotic shock and lysing of the 
protoplasts. 
 
Media was removed from 6-well plates containing HeLa cells at approximately 80 % confluency. 
Between 1-3 mL of protoplast solution was added to each well and the plate was centrifuged at 
1000 g for 10 min to lay the protoplasts onto the HeLa cells. The supernatant was carefully 
removed by aspiration, and 1 mL of 50 % polyethylene glycol 1000 (average molecular weight 
1000) was added to the side of the well. Plates were incubated for 3 min at room temperature and 
the PEG was removed by aspiration. Two gentle washes were performed to remove the PEG but 
leave the protoplast layer intact, using 2 mL of MEM without serum added to each well followed 
by aspiration. 2 mL of MEM / 5% Charcoal Dextran treated Calf Serum / Penicillin / 
Streptomycin / Kanamycin was added per well and plates were placed at 37 °C in a humidified 
incubator with 5 % CO2 for 4-6 h (during which most of the protoplast layer would lift off the 
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HeLa cells), then the media was replaced and ligand was added. After 24-48 h incubation, the 
media was removed, cells were washed with 2 mL PBS and collected by trypsinization. 
 
3.4.6. Flow Cytometry and FACS  
HeLa cells were exposed to a solution of trypsin / EDTA for 30-60 s until they began to exhibit a 
rounded morphology. The trypsin / EDTA was removed by aspiration and the cells were 
incubated for another 1-2 min and resuspended in MEM + 5% Charcoal Dextran stripped Calf 
Serum. Samples were pelleted by centrifugation for 5 min at 800 g, media was removed by 
aspiration, and cells were resuspended in 300-400 µL PBS / 5 mM EDTA. For monitoring 
purposes, cells were measured on a BD LSRII flow cytometer (Becton Dickinson, Franklin 
Lakes, NJ) using standard GFP/FITC filter sets. Analysis was performed using FCS Express 3 
software (De Novo Software, Los Angeles, CA). Events were gated on the region corresponding 
to single whole cells and the mean fluorescence for 10,000 cells was recorded. For isolation of 
positively expressing HeLa cells by fluorescence activated cell sorting (FACS), samples were 
analyzed on a FACSAria II flow cytometer (BD Biosciences, Franklin Lakes, NJ). Cells that 
expressed above the level of a negative control, or the top 1 % of cells, were collected into a tube 
containing MEM + 5% Charcoal Dextran stripped Calf Serum and 35000 non transformed HeLa 
cells to act as a carrier. 
 
Plasmid-containing HeLa cells were pelleted and resuspended in 50 µL of 10 mM tris-HCl with 
0.2 mg/mL tRNA. 50 µL of Qiagen miniprep buffer P2 was added to lyse the cells, followed by 
70 µL of buffer P3. The solution was centrifuged at 13,000 rpm for 5 min and the supernatant 
was transferred to a new tube. An equal volume of 25:24:1 phenol:chloroform:isoamyl alcohol 
was added and vortexed. After centrifuging for 1 min, the top aqueous layer was transferred to a 
new tube and an equal volume of chloroform was added, vortexed, centrifuged for 1 min, and the 
top layer removed to a new tube. 1 µL of 20 mg/mL glycogen was added, followed by one 
volume of isopropanol. The tube was mixed and incubated to -80 °C for 30 min and then 
centrifuged for 10 min. The supernatant was removed and the pellet washed with 200 µL 70 % 
ethanol. The tube was centrifuged for a further five min, the supernatant was removed, and the 
pellet was air dried. The isolated plasmid was resuspended in 10 µL 10 mM tris-HCl, 2 µL was 
electroporated into DH5α E. coli cells which were plated on LB + Ampicillin plates. 
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3.4.7. Yeast Two-hybrid Screening  
Screening was performed as described previously (29). The first and second round of screening 
was performed at a concentration of 10-6 M hexylresorcinol, while the third round used 10-7 M. 
For the first round, saturation mutagenesis was applied individually to 19 sites of the wild type 
hERα-LBD: 343, 346, 347, 349, 350, 383, 384, 387, 388, 391, 404, 421, 424, 425, 428, 521, 
524, 525, and 528. For the second round, the first mutant G525T was used as a template and the 
remaining 18 sites were mutagenized. For the third round, the mutant G524T/A350M was used 
as a template and the remaining 17 sites were mutagenized. 
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Chapter 4: Gene Switch Targeting of the Endogenous VEGF-A Gene 
4.1 Introduction 
The promise of a well designed gene switch system is that it can be used to regulate not just 
artificial reporter genes, but any desired gene at its endogenous genome locus. This allows for 
specific induction or repression of a desired gene for research purposes or for gene therapy 
applications. A key component to gene targeting is the creation of specific DNA binding 
domains to effectively target the gene switch to the gene of interest. Ideally the DNA binding 
domain would be specific to a single site in the genome to avoid off target effects. The majority 
of research in this area has used the Cys2His2-type zinc finger domain due to its perceived 
modularity, with one finger interacting with three base pairs of DNA and tandem arrays of 
fingers binding longer regions (1, 2). Different approaches have been taken to engineer a DBD to 
a specific site including the use of phage display to engineer specific individual fingers, a 
bacterial two-hybrid screen, rational design, or a combination of these (3, 4, 5, 6, 7). 
 
The gene that was chosen for targeting in this thesis was Vascular Endothelial Growth Factor A 
(VEGF-A). VEGF-A plays a critical role in the development of blood vessels and the lymphatic 
system (8) and was identified by a number of groups as a factor that stimulates endothelial cell 
growth and increases permeability of the vascular system (9, 10, 11). By stimulating the 
formation of blood vessels during development, it plays an essential role, with loss of even one 
allele of this gene leading to embryonic lethality (12). In addition to its role in normal 
development, it is involved in wound healing, regulating hematopoietic stem cells, growth of the 
uterine lining, as well as in the development of tumors which require vascularization in order to 
grow. The ability to regulate VEGF-A levels has obvious clinical relevance with upregulation 
leading to better wound healing and treatment of ischemia, while downregulation could help 
potentially aid in the treatment of cancer and diabetic blindness (13, 14, 15). 
 
The natural regulation of VEGF-A is a multifaceted process occurring at both transcriptional and 
post-transcriptional levels. The gene consists of 8 exons with multiple variants being generated 
through alternative splicing of the transcribed mRNA (16). The promoter region contains binding 
sites for transcription factors including the Sp family, AP1, the estrogen and progesterone 
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receptors, and the hypoxia inducible factor (HIF). The binding of HIF-1 to the promoter is a 
main contributor to VEGF-A transcription and promotes the growth of vasculature into areas of 
hypoxia (17). The main transcriptional start site is located 1038 bp upstream of the traditional 
AUG start codon, however there is an alternate downstream transcriptional start, two cap-
independent internal ribosome entry sequences (IRES) (18, 19), and some isoforms generated 
through a CUG codon 499 bp downstream of the main transcriptional start (20). At the post-
transcriptional level, hypoxia acts to stabilize the VEGF-A mRNA through elements that bind to 
instability elements in the 3’ untranslated region (21, 22), while translation can be inhibited 
through the IFN-γ-activated inhibition of the translation complex (22). 
 
Due to the clinical relevance of altering VEGF-A levels, a number of groups have engineered 
artificial transcription factors to target the gene. A series of papers from Sangamo Biosciences 
showed that artificial zinc finger domains designed to bind to accessible regions of chromatin in 
the promoter could efficiently induce VEGF-A secretion in HEK293 cells by addition of the 
activation domain VP16 or p65, could repress expression by addition of a histone 
methyltransferase domain, functioned in a mouse model to stimulate angiogenesis and speed 
wound healing, and could be controlled using a modified progesterone responsive ligand binding 
domain (23, 24, 25, 26). One of the DBDs from this research was subsequently used to create a 
rapamycin inducible dimerizing gene switch (27). DNA binding domains designed from 
endogenous zinc fingers were used by Kim’s group to successfully induce or repress VEGF-A 
expression in HEK293 or in human tumor cells xenografted into mice (28, 29, 30). Sera’s group 
has also used constitutively acting gene switches to induce VEGF-A in HEK293 cells (31, 32). 
 
The goal of this chapter was to target the endogenous VEGF-A gene with an engineered ligand 
controlled gene switch, and identify design considerations that influence the performance. By 
using previously engineered DNA binding domains and the engineered DHB responsive ligand 
binding domain 4S, constructs were created that showed up to 17 fold induction of a VEGF-A 
promoter controlled luciferase reporter. Construct performance depended on the particular DBD 
used, the activation domain used, and the arrangement of the functional domains. When 
introduced into HeLa cells, the constructs resulted in successful ligand dependent VEGF-A 
induction of a few fold. A higher level of basal expression was observed when HEK293 cells 
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were assayed, and minimal induction was seen. Studies are continuing in order to identify the 
reasons for the discrepancy with previously published reports using HEK293. 
 
4.2 Results and Discussion 
4.2.1 Cloning of a Luciferase Reporter and Initial Gene Switch Constructs 
To begin engineering a gene switch capable of influencing the endogenous VEGF-A gene, a 
luciferase reporter was cloned to enable the characterization of constructs. A 3 kb length of the 
VEGF-A promoter / 5’ untranslated region was obtained by PCR from human genomic DNA and 
cloned into the pGL3 luciferase reporter vector. The cloned reporter has the first codon of the 
luciferase gene fused at the main translational start site of VEGF-A. Some initial gene switch 
constructs were made to test induction of the reporter. Liu et al. of Sangamo Biosciences had 
previously designed multiple zinc finger DNA binding domains targeted to VEGF-A (23), and 
one of these was used here. The VZ-8 (called herein VZ8) binds to the target GGGGAGGAT(c) 
which is 8 base pairs upstream from the main transcriptional start site of the VEGF-A gene. This 
domain was cloned with either the wild type ERα or engineered DHB responsive 4S ligand 
binding domain, and the presence or absence of p65 activation domain variants. As seen in 
Figure 4.1, all constructs showed ligand dependent induction of luciferase, indicating that both 
the reporter and the gene switches were functional. The addition of the full p65 activation 
domain (amino acids 282-551) increased the basal expression, while use of a reduced length of 
p65 (amino acids 451-551) showed low basal expression and a ten-fold induction for the 
construct p65(451-551)VZ8-4S. From these few constructs tested, it can be seen that the design 
of a gene switch can be optimized using factors such as the activation domain and the order of 
domains. 
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Figure 4.1. Induction of the luciferase reporter gene by VEGF-A targeting gene switches. Data is 
normalized such that the 0 M point for VZ8ER equaled 1. ER gene switches were exposed to differing 
levels of estradiol, while the 4S switches were exposed to DHB. 10 ng of gene switch, 690 ng of the 
luciferase reporter expression plasmid, and 100 ng of the β-galactosidase expression plasmid were 
lipofected into HeLa cells. 
 
The level of induction from the VEGF-A targeting constructs was markedly reduced compared to 
the GAL4 DBD-containing switches of previous chapters. This could be due to many factors 
including expression and solubility of the gene switch, affinity of the switch for the promoter, the 
presence of only one binding site in the VEGF-A promoter compared to the multiple sites in the 
synthetic GalTATA promoter, or dimerization of the gene switches. The effect of gene dosage 
was examined with a constitutively acting construct, nlsVZ8p65, containing a nuclear 
localization sequence fused to the DNA binding and activation domains. It was seen that a higher 
amount of gene switch plasmid transfection resulted in a higher induction of the luciferase 
reporter (Figure 4.2). Subsequent experiments typically used 100 ng of gene switch expression 
plasmid per well of a 24 well plate. 
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Figure 4.2. Effect of gene switch dosage on luciferase reporter induction. 
 
4.2.2 Construct Optimization 
To begin optimization of the gene switch for targeting VEGF-A, the effect of the activation 
domain was investigated. A number of activation domains are commonly used with engineered 
transcription factors and include the yeast GAL4, VP16 Herpes simplex viral protein, and the 
p65 subunit of the NF-kB transcription factor. While VP16 had been used in some of the 
previous constructs discussed in this thesis, an engineered version consisting of four copies of 
the VP16 minimal activation domain, called VP64, has been reported to have higher activity 
(33). The VP64 and p65 activation domains were cloned at the C-terminus of the GAL4 DNA 
binding domain and tested for their ability to induce transcription from the GalTATA-luciferase 
reporter. Both showed activity, with GAL-VP64 giving 80 fold induction and GAL-p65 showing 
over 11000 fold induction (Figure 4.3). The performance of an activation domain in engineered 
transcription factors varies depending on both the cell type and the particular construct design 
(23, 34, 35). Since the p65 construct gave the highest activity in the current system and is 
generally well-performing, this was used in further construct designs. Also for the current gene 
switch application, human components are preferred as they should have the lowest chance of 
stimulating an adverse immune response. 
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Figure 4.3. Comparison of VP64 and p65 activation domain activities. A GalTATA-Luciferase reporter 
was transfected into HeLa cells in the absence or presence of constructs containing the GAL4 DNA 
binding domain and either the VP64 or p65 activation domain. The data is the mean and standard error of 
of two independent experiments and is normalized to the reporter only condition. 
 
Naturally evolved activation domains, including that of p65, are often composed of sub-regions 
that each possesses activation characteristics. The human p65 protein is 551 amino acids long 
and the activation domain has been localized to the C-terminal region (36, 37, 38) and functions 
through binding to the general transcription factors TFIIB and TATA-binding protein (39). A 
large portion of the activation activity can be reconstituted by solely the last 30-40 amino acids, 
with additional regions of activity within 416-458 and 458-521 (37). To test the effect of these 
regions on the gene switch, different lengths of the p65 gene were cloned at the N-terminus of 
the VZ8-4S to create a construct that was induced by DHB and targeted the VEGF-A promoter. 
The p65 region affected both the basal and maximal level of expression (Figure 4.4). The longest 
region used (282-551) gave the second highest expression level but exhibited the highest basal 
level, thus giving a poor performance in this construct. Each of the individually identified 
activation regions (amino acids 417-459, 460-523, and 510-551) from Moore et al. (37) 
conferred a similar low basal level, and ligand dependent induction of 6-12 fold. The best region 
tested here was 451-551 which showed around 17-fold induction with ligand. These results are 
consistent with previous studies using the GAL-p65 constructs that showed that including 
residues upstream of about position 414 led to lower expression (36). 
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Figure 4.4. Effect of sub-regions of the p65 activation domain. Different regions of p65 (as indicated by 
their amino acid positions) were cloned into the gene switch p65-VZ8-4S and activation of a VEGF-A 
controlled luciferase reporter was monitored in the absence (0 M) or presence of 10-6 M DHB. Data is 
normalized such that the lowest value equaled 1. 
 
The effect of adding interdomain linkers was investigated, since linkers can influence the 
expression, folding, and function of proteins. Four linkers (1-GGSGT, 2-GGSGTGSGSG, 3-
FDRNRPS, and 4-MELAQRN) were selected from analyses of natural and artificial interdomain 
linkers (40, 41). Linkers 1 and 2 are glycine/serine-rich regions of 5 or 10 amino acids that are 
typical of the regions used in protein engineering to link two separate domains and are expected 
to allow flexibility of the domains. Linker 3 is an extended unstructured region, while linker 4 is 
a short helical region. These were inserted between the domains of the construct p65-VZ8-4S. As 
seen in Figure 4.5, the linkers did not influence the performance of the gene switch to a large 
extent. All constructs were functional and showed an induction of 5-10 fold. 
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Figure 4.5. Effect of linkers between the functional domains. Induction of a VEGF-A-Luciferase reporter 
by constructs differing in the linker region between functional domains. Data is the mean and standard 
error of the mean of two independent experiments and is normalized by setting the lowest value to 1.  
 
 
Figure 4.6. Domain reordering. Induction of a VEGF-A-Luciferase reporter in HeLa cells by constructs 
that differ by the arrangement of the functional domains p65 (6), VZ8 (V), and 4S (4). Data is the mean 
and standard error of the mean of two independent experiments and is normalized by setting the lowest 
value to 1. 
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The effect of domain order was examined by creating constructs with the order of the functional 
domains rearranged. A difference of around ten fold was observed in basal activity and around 
three fold for the level of induced expression. The best induction ratio was observed for the 
construct p65-4S-VZ8 with almost 17 fold activation (Figure 4.6). The arrangement of domains 
has been recognized as a significant modulator of gene switch performance (42). 
 
To improve the performance of the gene switches, different published DNA binding domains 
were investigated. The DBD used so far for targeting the VEGF-A gene, VZ8, consists of three 
zinc fingers and was engineered by Liu et al. (23). Another active DBD from this paper was 
VZ434 which binds to the sequence GGGGGTGAC, 434 bases downstream of the main 
transcriptional start site. This was constructed and cloned into the constitutive nlsVZ434p65 and 
ligand inducible p65(451-551)-VZ434-4S gene switches and compared with the corresponding 
VZ8 constructs in their ability to activate the VEGF-A-Luciferase reporter. The original VZ8 
constructs both performed better than those with VZ434, as seen in Figure 4.7. The nlsVZ8p65 
switch gave 17 fold induction compared to only 11 fold induction from nlsVZ434p65. However, 
both of these were lower than another DBD in the F435p construct which gave 40 fold induction. 
This construct contains a three finger DNA binding domain that was engineered by comparison 
to natural human zinc fingers, along with a hemagglutinin tag, nuclear localization sequence, and 
p65 activation domain (28). F435p binds to the sequence GGGNGGGGA which is present on the 
reverse strand of the VEGF-A promoter at positions -90 and -391 and on the forward strand at 
position -1345 upstream of the main transcriptional start site. The DHB inducible VZ8 construct 
gave 14 fold induction compared to 4 fold for the VZ434. 
 
The differences observed with the three published DBDs could be due to a number of reasons. 
The benefit of F435 over the other two DBDs could be because of the multiple binding sites in 
the promoter, which is known to increase the transcriptional activity (43). This is supported by 
the observation that the initial reported induction of F435p was only 4 fold with a VEGF-A-
Luciferase construct that extended to promoter position -950 (28), while a 40 fold induction was 
seen here using a promoter containing the additional upstream binding site. There is also the 
possibility that the HA tag on F435p is somehow improving performance. VZ434 was reported 
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to stimulate VEGF-A transcription to a greater extent than VZ8 in HEK 293 cells while the 
reverse was observed here in HeLa cells which could indicate a cell-type specific property. 
 
 
Figure 4.7. Effect of different DNA binding domains on induction of a VEGF-A-Luciferase reporter. For 
the constitutive switches (nlsVZ8p65, nlsVZ434p65, F435p) the uninduced value is for the reporter only 
and the induced value is for the presence of the switch. For the ligand inducible switches uninduced and 
induced are the values for the absence and presence of 1 µM DHB. Data is normalized to the reporter 
only value and is the mean and standard error of the mean of at least two samples. 
 
To determine if increasing the DBD to six fingers, capable of targeting an 18 bp sequence, would 
improve performance additional fingers were selected and constructed. A new zinc finger DNA 
binding domain, VZ3, was designed to bind downstream of VZ8. The targeted site is 
GGGGAGGAT c GCGGAGGCT, with the VZ8 sequence italicized and the VZ3 site underlined. 
Based on zinc finger designs from Sangamo Biosciences (6) three individual fingers were chosen 
to bind GCGGAGGCT. The nucleotide sequence bound by each finger and the amino acids in 
the finger (-1 to position 6 of the recognition site) were: F1 GCT (QSSDLTR), F2 GAG 
(RSDNLAR), F3 GCG (RSDDLTR). These were cloned into the scaffold of the N1 DBD from 
the Barbas group (33) and assembled into the constructs p65-4S-VZ3, p65-4S-VZ38, and p65-
4S-VZ3gggs8 which has a GGGS amino acid linker between the two sets of three fingers. All 
constructs were functional as indicated by the luciferase assay (Figure 4.8). The VZ3 domain led 
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to 8.5 fold induction of the VEGF-A luciferase reporter and was thus functional but less active 
than the VZ8 domain. When VZ3 and VZ8 were fused to form the six finger constructs, they 
showed lower levels of basal and induced expression, but showed a 14-15 fold induction. The 
new constructs did not, however, outperform the p65(451-551)-VZ8-4S gene switch.  
 
 
Figure 4.8. Creation of an extended DNA binding domain. A comparison of luciferase reporter induction 
by VZ8, the newly engineered VZ3, and two six finger combined domains.  
 
4.2.3 Gene Switch Expression and Localization  
To determine the expression of the VEGF-A targeting gene switch, it was investigated using 
western blotting. The constructs were seen to be expressed at similar levels with VZ8 containing 
constructs and GAL4 constructs both expressed, as well as the wild type ERα (Figure 4.9). The 
localization of a representative gene switch was examined by confocal fluorescence microscopy. 
The construct p65GAL4S was tagged with the yellow fluorescent protein at its C terminus and 
its expression in HeLa was visualized by confocal microscopy (Figure 4.10). By staining the 
cells with the DNA stain DAPI, the nuclei were visualized and the gene switch was observed in 
comparison. In the absence of DHB, the gene switch seemed to be localized around the nucleus 
or throughout the cytoplasm, while the presence of DHB seemed to stimulate a translocation into 
the nucleus. This is the expected mode of action for the gene switch as the construct needs to be 
present in the nucleus to stimulate transcription. 
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Figure 4.9. Western blot of gene switch expression. 100 ng of plasmid was transfected into HeLa cells 
and protein was isolated after 24 hours. Lane 1: p65(451-551)-VZ8-4S, lane 2:VZ8-ER, lane 3:GAL-L7E, 
lane 4: ERα, lane 5: molecular marker. 
 
 
Figure 4.10. Confocal fluorescence microscopy of a gene switch expressed in HeLa cells in the presence 
and absence of its ligand DHB. HeLa cells were transfected with a yellow fluorescent protein (EYFP, 
colored green in the figure) tagged p65GAL4S switch, fixed with formaldehyde, stained with DAPI 
(blue), and examined by microscopy. The top images are in the absence of DHB, and the bottom images 
are in the presence of DHB. 
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4.2.4 Bimolecular Fluorescence Complementation Analysis of Gene Switch Activity 
The wild type estrogen receptor alpha functions through dimerization. It is expected that the 
GAL4-LBD containing switches would also dimerize as GAL4 response element is bound by a 
homodimer of the activation domain. It is unknown whether the engineered zinc finger DNA 
binding domains act as a dimer, as the rationale for their use is to be able to recognize any given 
DNA sequence and not be constrained by a symmetrical binding site. The role of dimerization 
was proposed to be investigated through the use of bimolecular fluorescence complementation 
(BiFC). This technique relies on the ability of the green fluorescent protein and its derivatives to 
be cleaved at certain positions into two inactive fragments which can then reassociate to form a 
fluorescent signal. If these two fragments are fused to proteins that interact, the process can be 
detected by an increase in fluorescence. Many studies have used this technique to monitor 
protein-protein interactions in vivo (44).  
 
Constructs were made that contained either the N terminal or C terminal half of the yellow 
fluorescent protein EYFP, split at residue 155, fused to either the wild type ERα or a 
representative gene switch p65-GAL-4S. When coexpressed in HeLa cells and analyzed by flow 
cytometry, no increase over the non-fluorescent control was observed for the ERα constructs 
(Figure 4.11a), or for p65GAL4S constructs despite a fluorescent signal visible for the full length 
EYFP tagged switches (Figure 4.11b). Since another yellow fluorescent protein variant, Venus, 
had been shown to have better performance in BiFC applications (45), constructs were recloned 
using Venus fragments. When coexpressed and analyzed, the constructs gave a fluorescent 
signal, but it was mainly dependent simply on the level of plasmid transfected and showed very 
little of the expected ligand dependent signal (Figure 4.12). 
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Figure 4.11. EYFP fragment tagged gene switch constructs. (a) ERα tagged at the N or C terminus with 
the N or C terminal fragment of EYFP. (b) p65GAL4S tagged constructs. HeLa cells were transfected, 
incubated 2 days, and then exposed to estradiol or DHB ligand 2 hours before being analyzed by flow 
cytometry. 
 
 
Figure 4.12. Bimolecular fluorescence complementation of mVenus fragment tagged constructs. ER 
samples are Vn-ER coexpressed with ER-Vc at 20, 200, or 400 ng each construct per well of a 12 well 
plate. 4S samples are p65-GAL-4S-Vn and p65-GAL-4S-Vc coexpressed at 20, 200, or 400 ng. Samples 
were expressed in the absence of ligand, or in the presence of 10 nM estradiol (ER) or 1000 nM DHB 
(4S). 
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These results suggested that the BiFC approach was not suitable for the investigation of 
dimerization of the gene switches. The signal that was generated was more dependent on the 
fluorescent protein fragments used than the gene switch, and the results of the Venus constructs 
suggest a non-specific interaction. For these reasons, the approach was not pursued further. 
However, a fluorescent complementation ligand sensor was successfully created and is discussed 
in Chapter 5. 
 
4.2.5 Endogenous VEGF-A Targeting: Quantitative RT-PCR and ELISA 
The ultimate goal of the gene switch research was to successfully alter the expression of the 
endogenous VEGF-A gene. As such, the gene switch constructs were transfected into HeLa cells 
and the secretion of VEGF-A into the culture media was measured by ELISA (Figure 4.13). The 
hypoxia mimic cobalt chloride stimulated over a 3.5 fold induction of VEGF-A secretion into the 
media, while the constitutive switch nlsVZ8p65 caused an increase in secretion of over 2.5 fold. 
The introduction of the DHB induced p65(451-551)-VZ8-4S gave a slight increase in basal 
production of VEGF-A, but the addition of DHB led to twice the amount of expression compared 
to the β-galactosidase control. These induction ratios are lower than those reported for HEK293 
cells, which for the original constitutive VZ8 construct was 8 fold and around 40 fold induction 
was seen with a VZ434 construct and p65 activation domain (23). The F435p construct was 
reported to induce VEGF-A secretion 21 fold in HEK293 in transient transfection (28), while 
stable cell lines containing the rapamycin induced dimerizing switch with the VZ8 DBD showed 
25-1000 fold induction (27). It is possible that HeLa cells are less inducible than HEK293, 
however, when I transfected HEK293 cells, a large basal expression of around 500 pg/mL was 
seen with little induction in response to cobalt chloride or gene switch presence. This could be 
due to differences in the transfection reagent used, or culturing conditions. Both Liu et al. and 
Bae et al. used Lipofectamine (Invitrogen, Carlsbad CA) for their VEGF-A induction assays (23, 
28), however this reagent was replaced with a new formulation, Lipofectamine 2000, which was 
used in the current experiments. A subsequent paper from Sangamo Biosciences that used 
Lipofectamine 2000 also showed a high basal expression of 600 pg/mL in HEK293 (24). 
Experiments are ongoing to identify the cause of this discrepancy. 
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Figure 4.13. Induction of endogenous VEGF-A secretion by the action of a gene switch.  
 
When the induction of VEGF-A mRNA was monitored, an increase due to the action of the gene 
switch was observed (Figure 4.14). As monitored in HeLa cells by quantitative reverse 
transcription PCR, the cobalt chloride hypoxia mimic led to a 12 fold induction of mRNA, with 
both the constitutive switch nlsVZ8p65 and the p65(451-551)-VZ8-4S induced by DHB giving 
just over twofold induction. This is somewhat less than expected based on published data from 
HEK293 experiments, which showed 8 fold induction with a constitutive VZ8 construct (23).  
However, it is similar to a number of other functional constructs (28). 
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Figure 4.14. VEGF-A mRNA induction in HeLa cells monitored by quantitative RT-PCR. Samples are 
cells in the absence or presence of 100 µM cobalt chloride, or cells transfected with the constitutive 
nlsVZ8p65 or the inducible switch p65(451-551)-VZ8-p65 in the presence of 1 µM DHB. 
 
4.3 Conclusions and Outlook 
A ligand dependent gene switch was successfully used to upregulate the endogenous vascular 
endothelial growth factor A gene in cell culture. A number of factors were shown to influence 
the basal and induced levels of transcription from the gene switch including the DNA binding 
domain and activation domain that was used, and the order of arrangement of the domains in a 
switch. Further optimization of the gene switch could be performed to analyze whether each of 
these factors are independent, or if they interact in unpredictable ways within a construct or in 
different cell types. The difference in endogenous VEGF-A production in HEK293 cells between 
the current work and previously published reports remains to be solved, and experiments are 
ongoing to address this. 
 
The low level of induction observed with the reporter studies show the difficulties in regulating a 
natural promoter as compared to a model promoter. This could be partly due to the lack of the 
post-transcriptional control with the luciferase reporter that is functioning with the actual VEGF-
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A gene. These low induction levels are also likely to have contributed to the difficulties 
encountered in creating a mammalian screening system as discussed in Chapter 3. 
 
4.4 Materials and Methods 
4.4.1 Reagents 
DNA polymerase, restriction enzymes, and T4 DNA ligase were from New England Biolabs 
(Beverly, MA). Chemicals were from Sigma-Aldrich (Carlsbad, CA). Cell culture media were 
from the UIUC cell media facility (Urbana, IL) or Invitrogen (Carlsbad, CA). DHB ligand was 
synthesized by Victor Gonzalez. DNA miniprep and RNA isolation kits were from Qiagen 
(Valencia, CA). The VEGF-A ELISA kit was from PeproTech (Rocky Hill, NJ). One component 
ABTS peroxidase substrate was from KPL (Gaithersburg, MD). Lipofectamine 2000 was from 
Invitrogen (Carlsbad, CA). 
 
4.4.2 Cloning of Constructs 
Standard molecular techniques were used for cloning the constructs used (see Table 4.1). The 
VEGF-A luciferase reporter was made by cloning a PCR product from human genomic DNA 
covering the region -1978 to + 1038 of the VEGF-A promoter between the KpnI and NcoI sites 
of pGL3-Basic (Promega, Madison WI). Gene switches were constructed by PCR and restriction 
digestion. F435p was a gift from Changkyu Oh (Toolgen, Korea). 
 
4.4.3 Cell Culture and Transfection 
HeLa cells were grown in minimal essential medium (MEM) / 1 mM sodium pyruvate / 10% 
fetal bovine serum (FBS) in a humidified incubator at 37 °C with 5% carbon dioxide. When cells 
were 80-90 % confluent, they were trypsinized and split into 12-24 well plates with MEM media 
/ 1 mM sodium pyruvate / 5% charcoal dextran treated calf serum (CDCS). Cells were grown for 
24 hours until they were over 90% confluent and transfected using lipofectamine 2000. For the 
gene switch optimization experiments, 100 ng of gene switch was transfected into HeLa with 
100 ng β-galactosidase control vector and 600 ng VEGF-A-Luciferase reporter. Media was 
changed after 4-6 hours, ligand was added, and cells were incubated for 24 hours before lysis and 
detection of luciferase activity. 
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Table 4.1. Constructs used in this work. 
HZ Genotype Plasmid 
1676 DH5alpha VZ8-ER pCMV5 
1677 DH5alpha VZ8-ER-p65 pCMV5 
2021 DH5alpha nls-VZ8-p65 pCMV5 
3079 DH5alpha F435p 
3266 DH5alpha GAL-VP64 pCMV5 
3253 DH5alpha GAL-p65 pCMV5 
1679 DH5alpha VEGFa-Luciferase pGL3 
613 DH5alpha GalTATA-Luciferase pGL3 
1874 DH5alpha p65(510-551)-VZ8-4S pCMV5 
1875 DH5alpha p65(451-551)-VZ8-4S pCMV5 
1876 DH5alpha p65(282-551)-VZ8-4S pCMV5 
1877 DH5alpha p65(417-459)-VZ8-4S pCMV5 
1878 DH5alpha p65(373-459)-VZ8-4S pCMV5 
1879 DH5alpha p65(460-523)-VZ8-4S pCMV5 
3267 DH5alpha p65-Link1-VZ8-4S pCMV5 
3268 DH5alpha p65-Link2-VZ8-4S pCMV5 
3269 DH5alpha p65-Link3-VZ8-4S pCMV5 
3270 DH5alpha p65-Link4-VZ8-4S pCMV5 
3271 DH5alpha p65-Link1-VZ8-NheI-4S pCMV5 
3272 DH5alpha p65-Link1-VZ8-Link1-4S pCMV5 
3273 DH5alpha p65-Link1-VZ8-Link2-4S pCMV5 
3274 DH5alpha p65-Link1-VZ8-Link3-4S pCMV5 
3275 DH5alpha p65-Link1-VZ8-Link4-4S pCMV5 
3276 DH5alpha p65-4S-VZ8 pCMV5 
3277 DH5alpha 4S-p65-VZ8 pCMV5 
3278 DH5alpha 4S-VZ8-p65 pCMV5 
3279 DH5alpha nls-VZ434-p65 pCMV5 
3280 DH5alpha p65(451-551)-VZ434-4S pCMV5 
3281 DH5alpha p65-4S-VZ3 pCMV5 
3282 DH5alpha p65-4S-VZ38 pCMV5 
3283 DH5alpha p65-4S-VZ3gggs8 pCMV5 
3125 DH5alpha p65-GAL-4S-EYFP pCMV5 
3126 DH5alpha p65-GAL-4S-Yn pCMV5 
3127 DH5alpha p65-GAL-4S-Yc pCMV5 
3128 DH5alpha EYFP-p65-GAL-4S pCMV5 
3129 DH5alpha Yn-p65-GAL-4S pCMV5 
3130 DH5alpha Yc-p65-GAL-4S pCMV5 
3284 DH5alpha Yn-ER pCMV5 
3285 DH5alpha Yc-ER-pCMV5 
3286 DH5alpha ER-Yn pCMV5 
3287 DH5alpha ER-Yc pCMV5 
3288 DH5alpha Vn-ER pCMV5 
3289 DH5alpha ER-Vc pCMV5 
3290 DH5alpha p65-GAL-4S-Vn pCMV5 
3291 DH5alpha p65-GAL-4S-Vc pCMV5 
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4.4.4 Quantitative RT-PCR 
HeLa cells were transfected in a 6 well plate with 400 ng gene switch along with 3600 ng empty 
pCMV5 vector using Lipofectamine 2000. 1 µM DHB was added to samples containing the 
inducible switch. Untransfected cells were incubated in the absence or presence of 100 µM 
cobalt chloride. After 1 day of incubation, cells were trypsinized and collected. RNA was 
isolated using an RNeasy kit (Qiagen, Valencia CA), and treated with DNA-free (Ambion, 
Austin TX) to remove genomic DNA contamination. Quantitative RT-PCR was performed using 
a HotStartIT SYBR Green mastermix (USB, Cleveland OH) in a MiniOpticon thermal cycler 
(Bio-Rad, Hercules CA). VEGF-A was amplified with primers VEGFA-mRNA-F (GTG CAT 
TGG AGC CTT GCC TGG) and VEGFA-mRNA-R (ACT CGA TCT CAT CAG GGT ACT C) 
and normalized to β-actin with primers bACTIN-F (GCA CAG AGC CTC GCC TT) and 
bACTIN-R (GTT GTC GAC GAC GAG CG). 
 
4.4.5 ELISA 
The human VEGF ELISA development kit (PeproTech, Rocky Hill NJ) was used for the 
determination of VEGF-A secreted into the media of cell culture experiments. The capture 
antibody was diluted to 0.5 µg/mL with PBS and 100 µL was added per well of a MaxiSorp 96 
well plate (Nunc, Rochester NY) for incubation at room temperature overnight. The liquid was 
removed and wells were washed four times with 300 µL of wash buffer (0.05 % Tween-20 in 
PBS). 300 µL of blocking reagent, consisting of 1 % bovine serum albumin (BSA) in PBS, was 
added per well and the plate was incubated for 1 hour. Dilutions of the supplied human VEGF 
standard were made at concentrations of 0, 50, 100, 200, 400, 600, 800, and 1000 pg/mL in 
dilution buffer (0.05 % Tween-20, 0.1 % BSA in PBS). The blocking reagent was removed and 
wells were washed four times with 300 µL of wash buffer then 100 µL of standard or media 
sample was added to duplicate or triplicate wells, followed by a 2 hour incubation. Wells were 
washed and 100 µL detection antibody (diluted in dilution buffer to 0.25 µg/mL) was added and 
incubated for 2 hours. After washing, the avidin-HRP conjugate was diluted 2000 fold and 100 
mL was added per well and incubated 30 min. The plate was washed and 100 µL of one 
component ABTS peroxidase substrate was added and incubated. At 10 minute intervals the 
plate was scanned at 405 nm with correction at 650 nm using a Spectramax 190 microplate 
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reader (Molecular Devices, Sunnyvale CA). Data was used from a scan time when the corrected 
OD was less than 0.2 for the zero samples or 1.2 for the 1000 pg/mL sample. 
 
4.4.6 Western Blotting 
HeLa cells were split into a 24 well plate and grown overnight until almost confluent. Cells were 
transfected using lipofectamine 2000 with 100 ng of gene switch plasmid and 450 ng empty 
pCMV5 vector. After 5 hours of exposure to the lipofection mixture the media was replaced with 
fresh MEM / 5 % CDCS, and cells were incubated 24 hours. Cells were collected by 
trypsinization, resuspended in 100 µL PBS and lysed by freezing at -80 °C. The sample was 
thawed, pelleted to remove debris, and 0.5 µL of 100 mM phenylmethylsulfonyl fluoride was 
added to inhibit protein degradation. 5 µL of the lysate was added to an equal volume of 4x 
Laemmli buffer, boiled for 5 min, and centrifuged a full speed for 1 min. The sample was loaded 
on a 20% SDS-PAGE gel with a 4 % stack and underwent electrophoresis. The protein was 
transferred to a PVDF membrane via electroblotting and the membrane was blocked overnight at 
4 °C. The F10 antibody to ERα (Santa Cruz Biotechnology, Santa Cruz CA) was diluted 1/1000 
and incubated with the membrane for 1 hour. The membrane was washed three times and the 
secondary antibody incubation was performed with a goat antimouse antibody for 30 min. The 
blot was washed three times and developed using Western Blue stabilized substrate for alkaline 
phosphatase (Promega, Madison WI). 
 
4.4.7 Confocal Microscopy 
Hela cells were grown in MEM on glass cover slips in 6 well plates and transfected when they 
were 50 % confluent. 1000 ng gene switch with 3000 ng empty pCMV5 vector were lipofected 
using 7.5 µL Lipofectamine 2000 per well. The media was replaced after 6 hours and 1 µM DHB 
was added to the ligand condition. Cells were grown for 24 hours then fixed. Cover slips were 
rinsed with PBS, then incubated with 0.3 % Triton X-100 / 4 % formaldehyde in PBS for 7.5 
min, rinsed with PBS then incubated with 4 % formaldehyde in PBS for another 7.5 min, 
followed by three five minute washes with PBS. Cover slips were stored in PBS at 4 °C until 
use. Cells were stained with 1 µg/mL diamidino-2-phenylindole (DAPI) for 5 min, followed by a 
PBS wash. Cover slips were placed cell side down on a microscope slide and the corners were 
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fixed in place using clear nail varnish. Images were collected on a Zeiss confocal LSM510 
microscope using a FITC filter set for the EYFP tagged switch, and a bright field view for DAPI. 
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Chapter 5: Development of a Fluorescent Biosensor for Detection of 
Estrogenic Compounds 
5.1 Introduction 
Small molecules play essential roles in biology as metabolites, signaling compounds, and 
allosteric regulators of protein function and as such it is desirable to detect their presence and 
monitor their effects. As a member of the nuclear hormone receptor superfamily, the estrogen 
receptor alpha (ERα) acts as a ligand-regulated transcription factor that is involved in a wide 
range of physiological processes such as mammary gland development, fertility, bone growth 
and maintenance, and metabolism (1). Its canonical ligand is 17β-estradiol (E2) which binds the 
ligand binding domain (LBD) and induces a conformational change in the position of helix 12 
that stimulates dimerization, the recruitment of coactivators or corepressors, and produces an 
effect on gene transcription (2). ERα is also bound and influenced by a multitude of other steroid 
hormones and pharmaceuticals (Figure 5.1), as well as natural products and industrial chemicals 
(Figure 5.2) (3, 4, 5). As a result there has been much research into developing methods of 
identifying compounds that interact with ERα, which can be used to measure their 
concentrations, and also elucidate the conformational changes they induce. 
 
The ligands capable of binding to the ERα ligand binding pocket, and the structural mechanisms 
underlying binding, have been extensively investigated (6, 7). E2 is a four-ringed, hydrophobic, 
steroid molecule with hydroxyl groups (the A ring phenolic hydroxyl and the D ring hydroxyl) 
that form important contacts within the ligand binding pocket. Compounds with similar 
structures, especially those maintaining the phenolic A ring, can show measurable binding to the 
receptor. The primary endogenous compounds are 17β-estradiol, estriol, and estrone (along with 
its sulfated form) which can be metabolized by hydroxylation leading to the formation of 2-
hydroxy and 4-hydroxy estradiol (8). Diethylstilbestrol was an early synthetic estrogen drug 
whose use was discontinued after it was discovered to promote developmental defects and cancer 
following in utero exposure (9). Other pharmaceuticals that interact with the estrogen receptor 
include 4-hydroxytamoxifen, raloxifene, dienestrol, norethindrone, and ICI 182780.  
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Figure 5.1. Endogenous estrogens, pharmaceuticals, and steroid hormones. 
 
Some natural products and industrial chemicals exhibit estrogenic activity (Figure 5.2). 
Phytoestrogens such as genistein and daidzein from soy, and resveratrol from grapes, have been 
proposed to have beneficial health effects via an interaction with the estrogen receptor (10). 
Alternatively, there is a growing concern over the effect of organic compounds produced by the 
chemical industry. While a single phenol group does not show estrogenic activation, larger 
organic compounds such as bisphenol A, and the detergent byproducts tert-octylphenol and 
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nonylphenol do show such effects (5). It is of great interest to develop easy ways of measuring 
the estrogenic effect of the many compounds people come into contact with during their daily 
lives. 
 
Figure 5.2. Natural products and industrial chemicals discussed in this chapter, some of which are 
estrogenic. 
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Many techniques have been developed to monitor small molecules and their binding to proteins. 
These include biophysical techniques such as X-ray crystallography, nuclear magnetic resonance 
(NMR), microcalorimetry, mass spectrometry, and surface plasmon resonance which are 
reviewed elsewhere (11). Biosensors are a method of detection where the sensor is composed of 
biological material, acting either in vivo or in vitro. These can generally be classified as either 
systems that stimulate the induction of an easily measured reporter gene, or molecular systems 
that directly generate a signal themselves (12). 
 
Reporter genes have been used extensively both in fundamental studies of transcription and also 
as sensors (12, 13). They are popular due to their ease of measurement and their ability to be 
generalized for detection of different ligands, relying on the fusion of the reporter gene to a 
ligand-regulated promoter that results in transcriptional activation in the presence of the target 
ligand. Common examples include the genes chloramphenicol acetyl transferase, β-
galactosidase, bacterial luciferase, firefly luciferase, uroporphyrinogen III methyltransferase, β-
glucuronidase, and autofluorescent proteins such as the green fluorescent protein. These reporter 
gene assays are typically performed within easily grown hosts such as Escherichia coli, 
Saccharomyces cerevisiae, or mammalian cells in culture.  
 
Molecular biosensors are engineered proteins that contain segments of fluorescent proteins (14, 
15), bioluminescent proteins (16, 17), or enzymatic domains, or consist of purified protein that is 
monitored through optical or other means. Purified protein can be incubated with either a 
radiolabelled or fluorescently modified ligand, whose displacement can be monitored under the 
influence of the test ligand. Many applications have been developed using Fluorescence 
Resonance Energy Transfer (FRET), which can be used in living cells (18). This involves the 
nonradiative transfer of energy from an excited donor (such as cyan fluorescent protein) to an 
acceptor fluorophore (such as yellow fluorescent protein) over short distances of up to 10 nm and 
can therefore be used to monitor protein interactions or conformational changes within a protein. 
Bioluminescence resonance energy transfer (BRET) is similar but the donor is a luciferase 
enzyme that catalyzes the oxidation of a coelenterazine molecule (19). 
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Protein complementation assays are based on the interesting ability shown by a number of 
proteins to be cleavable at particular positions to produce two inactive fragments that are capable 
of reassociation to reproduce the functional protein (20). Examples include β-lactamase, β-
galactosidase, dihydrofolate reductase, luciferase, and fluorescent proteins. Bimolecular 
fluorescence complementation (BiFC) is a recently developed method for analyzing protein 
interactions based on the reconstitution of a functional fluorescent protein from non fluorescent 
fragments (21, 22). The reassociation is stimulated by co-localization of the fragments via fusion 
to two interacting proteins, thus forming the foundation of an assay for protein-protein 
interaction (Figure 5.3).  
 
Figure 5.3. Protein complementation assays. The top panel shows the splitting of a fluorescent or 
luminescent protein into non active fragments. The middle panel shows the reassociation of these 
fragments when they are brought into contact through attachment to dimerizing proteins. The third panel 
shows the reconstitution of fluorescence or luminescence via a ligand stimulated conformational change 
in a protein linked to both fragments. 
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Many biosensors and bioassays have been developed for detection of (or regulation via) 
estrogenic compounds (23, 24). Systems using reporter genes include fluorescent proteins such 
as green fluorescent protein (GFP) (25, 26, 27), β-galactosidase (28, 29, 30, 31, 32), β-lactamase 
(33), bacterial luciferase (34), and the yeast HIS3 enzyme (35). Competitive binding to ERα has 
been monitored with purified protein and 3H labeled estradiol (36), or fluorescent ligands (37, 
38). The native biological effects of estrogenic compounds have been monitored via gene 
transcription (39), growth of breast cancer MCF-7 cells (40), and induction of the vitellogenin 
protein in fish (41). Fluorescence assays have been developed by linking the ligand binding 
domain of ERα to fluorescent proteins and monitoring the stabilization of fluorescence by ligand 
binding (42), or monitoring the ligand controlled position of helix 12 by using FRET (43, 44, 
45). Protein complementation assays using luciferase have been established (46, 47, 48, 49), and 
a conceptually similar approach using removal of an interfering protein intein to regenerate a 
selectable thymidilate synthase enzyme was also successful (50, 51, 52, 53). 
 
The goal of this chapter was to construct and determine the utility of an estrogenic compound 
biosensor based on the technique of fluorescence complementation. A series of constructs were 
made consisting of different lengths of the ERα LBD flanked by two halves of the split 
fluorescent protein mVenus. When expressed in mammalian cells, certain of these constructs 
showed an increase in fluorescence in the presence of ligands known to bind the estrogen 
receptor, and some distinguished agonists from antagonists. The fluorescent induction began 
within an hour of ligand addition, and increased over 24 h of incubation. A good correlation 
between the expected relative binding affinities and the measured EC50 values of different 
compounds was seen, and the sensor allowed for the detection of environmental compounds of 
interest. 
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5.2 Results and Discussion 
5.2.1 Cloning of mVenus and Sensor Constructs 
To create the estrogenic compound biosensor, it was decided to use the fluorescent protein 
Venus since it is bright, shows fast maturation at 37 °C (54), and has been shown to perform well 
in bimolecular fluorescence complementation applications (55). The mutations F46L, F64L, 
M153T, V163A, and S175G were introduced into the EYFP plasmid to convert it to Venus, as 
well as the A206K mutation which inhibits the weak dimerization activity of GFP variants (56), 
thus producing the monomeric mVenus construct. This was then split at position 155 to produce 
the two non fluorescent fragments Vn (amino acids 1-154) and Vc (amino acid 155-239). 
Transfection studies where the plasmid constructs were introduced into HeLa cells and analyzed 
by flow cytometry confirmed that mVenus was expressed and fluorescent. The two fragments Vn 
and Vc, were not fluorescent when expressed independently but when co-expressed at high 
levels they exhibited spontaneous association to give a fluorescent signal (Figure 5.4). 
 
Figure 5.4. Fluorescence of mVenus and fragments in HeLa cells. Plasmid was lipofected into HeLa cells 
(along with β-galactosidase plasmid to bring the total DNA to 800 ng) in 24-well plates. Samples from 
left to right are β-galactosidase, 100 ng Vn, 100 ng Vc, 100 ng mVenus, 10 ng of Vn and Vc, 100 ng of 
Vn and Vc, 400 ng of Vn and Vc. 
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It was reasoned that by fusing the non fluorescent fragments to the ligand binding domain of 
ERα, the conformational change upon ligand binding would bring the fragments close enough to 
complement each other. This approach was analogous to that used for previously reported FRET 
and luciferase complementation sensors. A series of constructs (referred to in this chapter as 
constructs 1 to 6) were made consisting of the ligand binding domain of the estrogen receptor α 
flanked by Vn and Vc (Figure 5.5). The two starting points for the LBD were amino acid 
positions 281 and 312, and the ending points were 532, 549, or 595 giving six different 
constructs. Position 281 will include most of the hinge region upstream of the LBD and has been 
used as the fusion site in other sensors (43, 46), while position 312 is a few residues downstream 
of the LBD starting position and has been used successfully for the gene switches discussed in 
other chapters of this work. Position 532 was used as the end of the LBD for the sensor made by 
Muddana and Peterson and removes helix 12 (42), ending at 549 will remove the less understood 
F domain and was used as the fusion point for Paulmurugan and Ghambir’s luciferase 
complementation construct (46), as was the C-terminus of the receptor at position 595. (Book 6 
pg 55-74, 104-107, 125-146; Book 7 pg9-41) 
 
 
Figure 5.5. Sensor constructs 1 to 6. The sensors differ in the lengths of the estrogen receptor region. 
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5.2.2 Agonist and Antagonist Compound Evaluation 
Transfection of the six constructs into HeLa cells followed by exposure to 100 nM of known 
agonists (17β-estradiol, diethylstilbestrol, estriol, or β-zearalanol), the antagonist ICI 182780, or 
the selective estrogen receptor modulators (SERMs, whose agonist or antagonist effect depends 
on the tissue type (57)), 4-hydroxytamoxifen, and raloxifene revealed that each construct had 
different properties (Figure 5.6). Constructs 1 and 4 both had low basal fluorescence in the 
absence of ligands and showed minimal induction in their presence. The commonality between 
these constructs is their ending at position 532, which cleaves off helix 12 that is responsible for 
the ligand-dependent conformational change that normally activates the receptor. Construct 3 
also performed poorly, having a high basal fluorescence and only a slight increase upon the 
addition of ligand. Construct 6 had a low basal fluorescence and showed 9-fold induction with 
both agonists and antagonists. Constructs 2 and 5 seemed to exhibit some distinction between 
agonists and antagonists, a property that could be useful for pharmaceutical screening purposes. 
Construct 2 had high basal expression and a 15-30% decrease when in the presence of agonists, 
but an increase of 50-90% in the presence of antagonists. Construct 5 had a low basal signal with 
strong induction of 16-fold in the presence of the three antagonists, with a variable but lower 
induction to the agonists. The differences in basal fluorescence between the constructs could 
result from different spatial positioning of the two halves of mVenus, with closer arrangements 
allowing complementation in the absence of ligand that is enhanced or decreased by the 
conformational change upon agonist or antagonist binding. (Book 8 pg 26-43) 
 
The properties of fluorescence complementation used in this system of sensor compare favorably 
to previously reported sensors. It has the benefit of requiring no exogenous substrates to produce 
a signal, as opposed to the luciferase complementation sensor (46). The signal generated is 
simply an increase in fluorescence (similar to Muddana and Peterson’s sensor (42)) which is 
more robust and does not suffer from crosstalk that may occur with FRET assays due to 
absorption of energy by the acceptor fluorophore from the excitation laser instead of the donor 
fluorophore. The sensor is expressed in mammalian cells, as opposed to yeast or bacterial, 
meaning the transport of ligands into the cell is more appropriate. 
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Figure 5.6. Sensor construct performance with agonists and antagonists. All constructs (1-6) were 
transiently transfected into HeLa cells and exposed to ethanol vehicle or 100 nM of the agonists E2, 
diethylstilbestrol, estriol, or β-zearalanol, or the antagonist/ SERMs ICI 182780, 4-hydroxytamoxifen, or 
raloxifene. Data shown is the mean and standard error of the mean for two or more independent 
experiments. 
 
 
5.2.3 Fluorescence Signal Generation Time Course 
One of the important properties of an assay is the length of time it takes to give a positive signal. 
For this reason, the time course of signal generation for the fluorescence complementation 
biosensor was determined. Construct 6 was chosen for study as it showed the best induction 
properties. The sensor was transfected into HeLa cells and exposed to 100 nM 17β-estradiol for 
up to 24 h before the cells were fixed in formaldehyde for analysis by flow cytometry. The 
results show a 25 % ligand dependent induction within 1 h, 2 fold induction by 4 hours, and 9 
fold induction with a 24 h incubation in the presence of ligand (Figure 5.7). (Book 8, pg 14-32) 
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Figure 5.7. Time course of fluorescence signal generation of construct 6. HeLa cells were transiently 
transfected with construct 6 and exposed to 100 nM 17β-estradiol or ethanol vehicle for up to 24 hours, 
followed by formaldehyde fixation and flow cytometry. Data is the mean fold induction between ligand 
and no ligand conditions at each time point, with the standard error of the mean for three independent 
experiments. 
 
The time for signal generation is intermediate compared to other reported biosensors. The 
fluorescence complementation approach has an inherent delay after ligand binding due to the 
length of time required for generation of the Venus fluorophore; however this is on the order of 
tens of minutes (54). The signal from a FRET sensor is very fast since the fluorophores are 
already formed, so the time taken to measure a change in emission ratio reflects only the time for 
ligand binding and the conformation change of helix 12 and can be detected within 4-20 minutes 
(44). Split luciferase systems in general are also capable of signal changes on the timescale of 
minutes (17), however the estrogen biosensor by Paulmurugan et al using this system (46) took 
between 6 and 12 hours to give a measurable signal, with maximal induction after 24 h which is 
similar to the sensor described here. The 24 hours required for maximal induction of the 
fluorescence and luciferase complementation signal suggest that these assays are not simply 
monitoring a conformation change. It is possible that the constructs are stabilized by ligand 
binding and the length of time reflects the growing accumulation of newly synthesized sensor. 
The fluorescence complementation assay is faster than growth based assays for estrogenic 
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compounds such as the E-SCREEN method which monitors growth of the human cell line MCF-
7 after six days (40). 
 
5.2.4 Vn-ER312-595-Vc Ligand Titration 
As construct 6 was seen to perform well, it was decided to test its sensitivity to a number of 
different ligands. The ligand binding curves are shown in Figure 5.8, and the calculated 
concentration at half maximal induction (EC50) is shown in Table 5.1. The EC50 values were 
plotted against known relative binding affinities (RBA) for the compounds (Carlson and 
Katzenellenbogen, unpublished data; and (3)) (Figure 5.9). (Book 8 pg 1-20) 
 
 
Figure 5.8. Ligand titration of compounds with construct 6. 
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Table 5.1. Concentration of ligand required to reach half maximal induction of construct 6 (nd = not 
determined). 
Ligand EC50 ± SEM (nM) 
17β-Estradiol 8.1 ± 1.5 
Diethylstilbestrol 2.2 ± 0.37 
Genistein 220 ± 11 
Dienestrol 4.4 ± 0.87 
ICI182780 31 ± 13 
Progesterone nd 
13-Cis retinoic acid nd 
Hydrocortisone nd 
Testosterone 14000 ± 3700 
4-Hydroxyestradiol 58 ± 4.7 
2-Hydroxyestradiol 550 ± 100 
Estriol 36 ± 11 
Norethindrone 880 ± 260 
Estrone sulfate 230 ± 27 
4-Hydroxytamoxifen 2.5 ± 0.73 
17α-Estradiol 51 ± 1.7 
 
 
Figure 5.9. Scatter plot of RBA against EC50 determined by construct 6. The RBA of 17β-estradiol is set 
to be 100. 
 
There was a reasonable correlation between the results obtained here and previously determined 
binding data, as can be seen in Figure 5.9. The sensitivity toward 17β-estradiol was lower than 
some measurements, although the value depends on the assay used ranging from 6 pM when 
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monitoring MCF-7 cell growth, up to nM values (41). The 8 nM EC50 was similar to that 
reported with FRET biosensors (43, 44). The results showed that binding of diethylstilbestrol, 
dienestrol, and 4-hydroxytamoxifen was higher than 17β-estradiol, as expected. Progesterone, 
13-cis retinoic acid, and hydrocortisone were not expected to bind and indeed gave minimal 
response. Some low affinity ligands showed detectable binding, such as testosterone at 
micromolar and higher, and genistein at 100 nM and higher which was not detected by some 
sensors (46). 
 
5.2.5 Detection of Exogenous Endocrine Active Substances 
Having shown that construct 6 functioned well with a range of compounds, it was desired to test 
the binding of some environmental compounds. Figure 5.10 shows the results for compounds 
reported to be negative for estrogenic activity and also those expected to produce a response. 
Phenol, 1-naphthol, and 2-naphthol are commonly used in organic synthesis and the plastic 
industry, butylated hydroxytoluene is an antioxidant, while carbofuran and carbaryl are 
insecticides. All of these have organic ring structures but do not show estrogenic activity (40). 
When tested here at 0.01 mM, none showed an increase in fluorescence with construct 6; 
however the naphthols and carbaryl showed a small increase in fluorescence at 0.1 mM. 
Phytoestrogens are compounds derived from plants and can be consumed in amounts sufficient 
to produce plasma concentrations up to 10 µM (10). Daidzein is found in soy and is acted on by 
microorganisms in the gut to produce equol, both of which caused an increase in fluorescence at 
micromolar concentrations. Resveratrol is found in grapes and has been proposed to have many 
beneficial health effects but only weakly activated the sensor at 10 µM. The Fusarium fungus 
can grow on corn and other crops and produces zearalanone and its derivative β-zearalanol 
which is strongly estrogenic (5), as can be seen in Figure 5.10b. The nonionic detergent 
byproducts tert-octylphenol and nonylphenol were both detected at sub-micromolar levels, along 
with bisphenol A. The pesticide o,p’DDT and a PCB compound also displayed activation 
beginning at micromolar levels. (Book 8 pg 32-43) 
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Figure 5.10. Detection of environmental chemicals using construct 6. (a) Compounds reported to not 
show estrogenic activity were tested at 0.01 mM and 0.1 mM, along with vehicle (0 M) and 100 nM 
estradiol (E7) as controls. (b) Compounds reported to show estrogenic activity: daidzein, equol, 
resveratrol, β-zearalanol, tert-octylphenol, nonylphenol, bisphenol A (BPA), op’DDT, and 2,4,6 trichloro 
4-hydroxy PCB (PCB) were tested at concentrations up to 10 µM. Data was normalized to the 100 nM 
estradiol condition and is shown as the mean and standard error of the mean. 
 
5.3 Conclusions and Outlook 
The fluorescent complementation biosensor for estrogenic compounds described here proved to 
perform well. It was capable of detecting the binding of ligands whose affinity varied from 
nanomolar to tens of micromolar. Construct 6 could detect both agonists and antagonists from a 
range of sources, while construct 2 could distinguish antagonists from agonists. These properties 
could be useful for screening programs aiming to identify novel drugs targeting the ERα. Future 
directions could include further optimization of the construct in terms of linker regions and the 
best boundaries of the LBD region. For screening purposes, the sensor could be stably integrated 
into a human cell line such as HEK 293 to avoid the need for transfection. 
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5.4 Materials and Methods 
5.4.1 Reagents 
All DNA polymerases, restriction enzymes, and T4 DNA ligase were from New England Biolabs 
(Ipswich, MA). Cell media, fetal bovine serum, and charcoal dextran treated calf serum were 
obtained from the University of Illinois cell media facility (Urbana, IL). Opti-MEM media and 
lipofectamine 2000 were from Invitrogen (Carlsbad, CA). Carbamyl and carbofuran were from 
Chem Service (West Chester, PA), and raloxifene was from Tocris Bioscience (St Louis, MO). 
Other chemicals were from Sigma (St Louis, MO). 
 
5.4.2 Cloning of Constructs  
Unless otherwise stated, standard molecular biology techniques were used. A monomeric version 
of Venus fluorescent protein was constructed by mutagenesis of EYFP. Primers mVenus-Asmbl 
F1 (AACGTCTATATCACCGCCGACAAGCAGAAGAACGGCATCAAGGCCAACTTCAA 
GATCCGC), R2 (GGTAGTGGTCGGCGAGCTGCACGCCGCCGTCCTCGATGTTGTGGCG 
GATCTTGAAGTTGG), F3 (TCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACG 
GCCCCGTGCTGCTGCCCGACA), and R4 (CTTTGCTCAGCTTGGACTGGTAGCTCAGGT 
AGTGGTTGTCGGGCAGCAGCAC) were assembled using overlap extension and the product 
was used as a megaprimer on EYFP plasmid to extend to the C-terminus. This C-terminal 
fragment was used as a megaprimer with mVenus F64L-For (AAGCTGCCCGTGCCCTGGCCC 
ACCCTCGTGACCACCCTGGGCTAC) on EYFP. The N-terminal fragment was created by 
PCR with primers Cherry-For-KpnI (AAAAAAGGTACCATGGTGAGCAAGGGCGAGGAG) 
and mVenus F46L-Rev (CCAGGGCACGGGCAGCTTGCCGGTGGTGCAGATCAGCTTCAG 
GGT), and was then used with the 64 C-terminal fragment to fill in the complete mVenus with 
EYFP as a template. The gene was digested with KpnI and BamHI and ligated into the vector 
pCMV5. The mVenus gene was split into fragments 1-154 and 155-239 by PCR of Vn with 
Cherry-For-KpnI and mVn154-Stop-Rev-BamHI (TTTTTTGGATCCTCAGGCGGTGATATA 
GACGTTGTGGCT), and PCR of Vc with EYFP155-For-KpnI (AAAAAAGGTACCATGGCC 
GACAAGCAGAAGAAC )and EGFP-Rev-BamHI (TTTTTTGGATCCTTACTTGTACAGCTC 
GTCCATGCCG), both of which were cloned into pCMV5. For cloning of the sensor constructs, 
the Vn-SalI-Vc-pCMV5 vector was constructed to insert the SalI site into mVenus-pCMV5 with 
Cherry-For-KpnI + mVenus154noStopRevSalI (AAAAAAGTCGACGGCGGTGATATAGAC 
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GTTGTGGCT); and mVenus155-SalI-For (AAAAAAGTCGACATGGACAAGCAGAAGAAC 
GGCATCAAGGCCAA) + EGFP-Rev-BamHI. The estrogen receptor α ligand binding domain 
regions were amplified by PCR with combinations of the forward primer ER281-For-SalIonly 
(AAAAAAGTCGACATGGGGTCTGCTGGAGACATGAGAGCT) or ER312-For-SalI (AAAA 
AAGTCGACGCCGACCAGATGGTCAGTGC), and reverse primer ER532-noStop-Rev-SalI 
(AAAAAAGTCGACGTTCTTGCACTTCATGCTGTACAGATG), ER549-noStop-Rev-SalI (A 
AAAAAGTCGACTAGGCGGTGGGCGTCCAGCAT), or ER595-noStop-Rev-SalI (AAAAAA 
GTCGACGACTGTGGCAGGGAAACCCTCT), and were cloned into the SalI site of Vn-SalI-
Vc-pCMV5. See Table 5.2 for constructs used here. 
 
Table 5.2. Constructs used in this work. 
HZ Genotype Plasmid 
2170 DH5alpha mVenus pCMV5 
2171 DH5alpha Vn pCMV5 
2172 DH5alpha Vc pCMV5 
3235 DH5alpha Vn-ER281-532-Vc pCMV5 
3236 DH5alpha Vn-ER281-549-Vc pCMV5 
3237 DH5alpha Vn-ER281-595-Vc pCMV5 
3238 DH5alpha Vn-ER312-532-Vc pCMV5 
3239 DH5alpha Vn-ER312-549-Vc pCMV5 
2243 DH5alpha Vn-ER312-595-Vc pCMV5 
 
5.4.3 Cell Culture and Transfection 
HeLa cells were grown in minimal essential medium (MEM) / 1 mM sodium pyruvate / 10% 
fetal bovine serum (FBS) in a humidified incubator at 37 °C with 5% carbon dioxide. When cells 
were 80-90 % confluent, they were trypsinized and split into 12-well plates with 1 mL per well 
of MEM media / 1 mM sodium pyruvate / 5% charcoal dextran treated calf serum (CDCS). Cells 
were grown for 24 hours until they were over 90% confluent and transfected using lipofectamine 
2000. Modifications were made to the standard protocol to minimize cell toxicity and optimize 
induction levels from sensor constructs. Typically, 1.5 µL lipofectamine 2000 was resuspended 
in 48.5 µL OptiMEM and incubated at room temperature for 10 min, then 50 ng of the sensor 
plasmid with 750 ng of the plasmid encoding β-galactosidase resuspended in 50 µL Opti-MEM 
was added and the mixture was incubated for 30 minutes and added to a well of HeLa cells. Cells 
were grown for 18 h after which the media was changed to MEM media / 1 mM sodium pyruvate 
/ 5% CDCS plus the desired ligand. After a further 30 hours of growth, cells were analyzed by 
flow cytometry. 
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5.4.4 Flow Cytometry 
Adherent cells were exposed to a solution of trypsin/EDTA for 30-60 s until they began to 
exhibit a rounded morphology. The trypsin/EDTA was removed by aspiration and the cells were 
incubated for another 1-2 min and resuspended in MEM + 5% CDCS. Samples were pelleted by 
centrifugation for 5 min at 800 ×g, media was removed by aspiration, and cells were resuspended 
in 300-400 µL PBS/5 mM EDTA. Cells were measured on a BD LSRII flow cytometer (Becton 
Dickinson, Franklin Lakes, NJ) using standard GFP/FITC filter sets. Analysis was performed 
using FCS Express 3 software (De Novo Software, Los Angeles, CA). Events were gated on the 
region corresponding to single whole cells and the mean fluorescence for 10000 cells was 
recorded. 
 
5.4.5 Agonist and Antagonist Discrimination  
Constructs 1-6 (ligand binding domain regions 281-532, 281-549, 281-595, 312-532, 312-549, 
312-595) were transiently transfected by lipofection into HeLa cells. Samples were treated with 
no ligand, agonists (17β estradiol, diethylstilbestrol, estriol, or β-zearalanol), or antagonists / 
selective estrogen receptor modulators (ICI 182780, 4-hydroxytamoxifen, or raloxifene). Flow 
cytometry was performed and the average population fluorescence determined. Data was 
normalized by dividing by the sum of the six no ligand conditions. 
 
5.4.6 Time Course of Fluorescence Signal Generation  
Construct 6 (Vn-ER312-595-Vc) was transiently transfected by lipofection into HeLa cells. After 
18 hours, the media was changed and 1 µL of 10-4 M 17β estradiol or ethanol was added to give 
a final ligand concentration of 10-7 M or 0 M. After 0, 1, 2, 4, 8, or 24 h of ligand exposure, cells 
were trypsinized, pelleted, and resuspended in 200 µl PBS and 1 mL of 3.6 % formaldehyde in 
PBS was added. Cells were fixed for 10 minutes, after which they were pelleted, resuspended in 
300-400 µL PBS/5 mM EDTA, and stored at 4 °C until analysis by flow cytometry. 
 
 
5.4.7 Ligand Titration  
Construct 6 (Vn-ER312-595-Vc) was transiently transfected by lipofection into HeLa cells. After 
18 hours, the media was changed and varying concentrations of the following ligands were 
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added: 17β-estradiol, diethylstilbestrol, genistein, dienestrol, ICI182780, progesterone, 
testosterone, 4-hydroxyestradiol, 2-hydroxyestradiol, estriol, norethindrone, estrone sulfate, 4-
hydroxytamoxifen, and 17α-estradiol. Cells were analyzed by flow cytometry and the average 
population fluorescence was determined and normalized such that the 10-7 M 17β-estradiol value 
was equal to 1. Ligand titration curves were plotted using OriginPro 8 (OriginLab Corporation, 
Northampton, MA), which were fitted to determine the concentrations of half-maximal induction 
(EC50). Relative binding affinities for the compounds were determined by Kathryn Carlson using 
recombinant ERα (Carlson and Katzenellenbogen, unpublished data). 
 
5.4.8 Environmental Compound Detection  
Construct 6 (Vn-ER312-595-Vc) was transiently transfected by lipofection into HeLa cells. After 
18 hours, the media was changed and varying concentrations of the following ligands were 
added: daidzein, equol, resveratrol, β-zearalenol, p-tert-octylphenol, nonylphenol, bisphenol A, 
ortho-para’-DDT, 2,4,6 trichloro 4-hydroxy PCB, phenol, 1-naphthol, 2-naphthol, carbaryl, or 
carbofuran. After 30 hours, cells were analyzed by flow cytometry. 
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